



Damage-associated molecular patterns in trauma

Borna Relja^{1,2} · Walter Gottlieb Land³

Received: 15 May 2019 / Accepted: 27 September 2019 / Published online: 14 October 2019
© The Author(s) 2019

Abstract

In 1994, the “danger model” argued that adaptive immune responses are driven rather by molecules released upon tissue damage than by the recognition of “strange” molecules. Thus, an alternative to the “self versus non-self recognition model” has been provided. The model, which suggests that the immune system discriminates dangerous from safe molecules, has established the basis for the future designation of damage-associated molecular patterns (DAMPs), a term that was coined by Walter G. Land, Seong, and Matzinger. The pathological importance of DAMPs is barely somewhere else evident as in the posttraumatic or post-surgical inflammation and regeneration. Since DAMPs have been identified to trigger specific immune responses and inflammation, which is not necessarily detrimental but also regenerative, it still remains difficult to describe their “friend or foe” role in the posttraumatic immunogenicity and healing process. DAMPs can be used as biomarkers to indicate and/or to monitor a disease or injury severity, but they also may serve as clinically applicable parameters for optimized indication of the timing for, i.e., secondary surgeries. While experimental studies allow the detection of these biomarkers on different levels including cellular, tissue, and circulatory milieu, this is not always easily transferable to the human situation. Thus, in this review, we focus on the recent literature dealing with the pathophysiological importance of DAMPs after traumatic injury. Since dysregulated inflammation in traumatized patients always implies disturbed resolution of inflammation, so-called model of suppressing/inhibiting inducible DAMPs (SAMPs) will be very briefly introduced. Thus, an update on this topic in the field of trauma will be provided.

Keywords DAMP · SAMP · Danger · Inflammation · Trauma

Abbreviations

AM	Alveolar macrophage	COPD	Chronic obstructive pulmonary disease
APC	Activated protein C	CLP	Cecal ligation and puncture
ARDS	Acute respiratory distress syndrome	CLR	C-type lectin receptor
ATP	Adenosine triphosphate	CNS	Central nervous system
BAL	Bronchoalveolar lavage fluid	CSF	Cerebrospinal fluid
CARS	Compensatory anti-inflammatory response syndrome	CXCL	Chemokine (C-X-C motif) ligand
CD	Cluster of differentiation	CypA	Cyclophilin A
cfDNA	Cell-free DNA	CytC	Cytochrome C
		DAMP	Damage-associated molecular pattern
		DIC	Disseminated intravascular coagulation
		DNA	Deoxyribonucleic acid
		EV	Extracellular vesicles
		HMGB	High-mobility group box
		HSP	Heat shock protein
		ICU	Intensive care unit
		IL	Interleukin
		IL-1R	Interleukin-1 receptor
		IS	Immunosuppression
		LPS	Lipopolysaccharide
		MAPK	Mitogen-activated protein kinase
		MBL	Mannose binding lectine

✉ Borna Relja
info@bornarelja.com

¹ Experimental Radiology, Department of Radiology and Nuclear Medicine, Otto von Guericke University Magdeburg, Magdeburg, Germany

² Department of Trauma, Hand and Reconstructive Surgery, University Hospital Frankfurt, Goethe University Frankfurt am Main, 60590 Frankfurt, Germany

³ Molecular ImmunoRheumatology, INSERM UMR_S1109, Laboratory of Excellence Transplantex, University of Strasbourg, Strasbourg, France

MHC	Major histocompatibility complex
Mincle	Macrophage-inducible C-type lectin
MIP	Macrophage-inflammatory protein
miRNA	MicroRNA
MODS	Multiple organ dysfunction syndrome
MOF	Multiple organ failure
MPO	Myeloperoxidase
mRNA	Messenger RNA
mtDNA	Mitochondrial DNA
MyD88	Myeloid differentiation primary response 88
NET	Neutrophil extracellular traps
NF- κ B	Nuclear factor “kappa-light-chain-enhancer” of activated B cells
NLR	NOD-like receptor
NLRP	Pyrin domain-containing nucleotide oligomerization receptor (NLR)
NOD	Nucleotide oligomerization domain
nRNA	Nuclear RNA
PAMP	Pathogen-associated molecular pattern
PMNL	Polymorphonuclear leukocytes
PRR	Pattern recognition receptor
RAGE	Receptor for advanced glycation end products of proteins
ROS	Reactive oxygen species
RNA	Ribonucleic acid
SAMP	Suppressing/inhibiting inducible DAMP
SAP130	Spliceosome-associated protein 130
SCI	Spinal cord injury
SIRS	Systemic inflammatory response syndrome
ST2	Orphan receptor serum stimulation 2
TBI	Traumatic brain injury
Th	T-helper cell
TLR	Toll-like receptor
TNF	Tumor necrosis factor
WT	Wild type

Introduction

Traumatic injury is one of the major contributors to worldwide mortality as well as one of the world’s most relevant but neglected health concerns [1, 2]. Multiply injured or polytraumatized patients most frequently die either immediately or early within only of a few hours after the traumatic insult due to their injury severity, severe traumatic brain injuries (TBI), and/or exsanguination, or in the later post-injury phase due to inflammation-related complications, which affect the immune system homeostasis, resulting in, e.g., sepsis, septic shock, or multiple organ failure (MOF) [2–6]. Adjacent to physical factors, which are intensely treated in the intensive care units (ICU), in case of survival, the multiply injured patient may suffer from serious impairments in cognitive, psychological, or psychosocial issues [7–9].

Over the last decades, several experimental (poly)trauma models which combine different injury patterns have been developed and applied to study and understand the basic pathophysiology of the posttraumatic sequelae in polytraumatized patients. While the primary impact can only be addressed by injury prevention, the later detrimental sequelae may be prevented by an abrogation of the posttraumatic course [10, 11]. The typical pathophysiological course of traumatized patients under ICU treatment is characterized by a systemic inflammatory response to severe injury that begins immediately after trauma, and which involves complex interactions across the hemostatic, inflammatory, endocrine, and neurological systems [3, 12, 13]. Modern notions hold that this clinically observed so-called systemic inflammatory response syndrome (SIRS) reflects an uncontrolled overshooting systemic innate immune response caused by polytrauma-induced emission of large amounts of so-called damage-associated molecular patterns (DAMPs) which circulate systemically to affect the whole body of the patient [3, 12–15]. The term DAMP was coined in 2003 by Land [15]. And it is apparently the DAMPs which lead to the catastrophe of the sterile hyperinflammatory, sepsis-like, life-threatening SIRS, which is most often associated with organ failure, MOF, or multiple organ dysfunction syndrome (MODS) [12, 13, 16]. Typically, this DAMP-induced systemic cytokine/chemokine-mediated hyperinflammatory response to severe trauma is associated with an intense and long-lasting counterbalancing compensatory anti-inflammatory response syndrome (CARS) resulting in posttraumatic immunosuppression (IS) [3, 5, 17–19]. CARS can be regarded as a disorder caused by a hyper-resolution of hyperinflammation in terms of a mirror-imaged counter-regulation of SIRS. Thus, for several decades research on posttraumatic complications was based on a biphasic posttraumatic inflammation model. The central pathophysiological principle there was to find the balance between a qualitative defense against invasive putative pathogens and additionally reducing collateral damage by immune cells [20–22]. Of note, however, instead of a previously assumed biphasic inflammatory response consisting of an initial proinflammatory and a subsequent counterbalancing anti-inflammatory response, hyper-resolving processes are now considered to occur simultaneously with hyperinflammation. There is presumably only a slight delay between initial hyperinflammation and the following hyper-resolution, which is possibly caused by the production of suppressing/inhibiting inducible DAMPs (SAMPs) by already DAMP-activated/initialized responses of innate immune cells [23]. Recently, this novel term accomplishing the DAMPs/SAMPs post-injury response was coined by Land [23]. The posttraumatic course of this inflammatory response is briefly represented in Fig. 1.




Fig. 1 Brief concept of posttraumatic inflammatory response with the involved damage-associated molecular pattern (DAMPs) and suppressing/inhibiting inducible DAMPs (SAMPs) and their release/

activation as well as hypothesized kinetics upon trauma. CARS: compensatory anti-inflammatory response syndrome; SIRS: systemic inflammatory response syndrome

SIRS

The recognition of DAMPs by immune cells initiates an acute hyperinflammatory condition of SIRS that induces physiological changes such as hypothermia or hyperthermia, elevated heart rate, and leukocytosis/leukocytopenia [24, 25]. The uncontrolled or protracted clinical signs of SIRS constitute a risk factor for organ failure, delayed hospital-acquired infections as well as occasionally MOF after trauma [26–28]. The concept of SIRS was introduced in early 1990s and charged with the task of developing an easy-to-apply set of clinical parameters, as well as biomarkers, to improve the early identification of potential candidates for clinical trials and new treatment strategies for sepsis, as well as for the identification of patients at risk of infectious complications, respectively [25]. Thus, since three decades, the knowledge on the complex pathophysiological and posttraumatic inflammatory response contributing to the development of post-injury complications is growing [29–32]. Numerous cellular and humoral proinflammatory mediators including complement factors are markedly elevated in patients suffering from SIRS and associated complications on the other hand. In general, SIRS is classically dominated by overwhelming hyperinflammatory processes which are characterized by elevated circulating levels of multiple powerful cellular and humoral proinflammatory

mediators. Of those, notably in the experimental and clinical sepsis-associated SIRS, cytokines (e.g., tumor necrosis factor (TNF), interleukin (IL)-1 α , IL-1 β , and IL-6), chemokines, growth factors, adhesion molecules, gaseous substances, vasoactive peptides, and cell stress markers have been identified and analyzed [33]. After the concept of SIRS was created, a number of publications emerged heralding the efficacy of SIRS in predicting outcomes after trauma [34, 35]. Accumulating evidence indicates that SIRS associated with MOF is the result of traumatic injury-induced either accidental or regulated cell death such as necroptosis, serving as a robust source for emission of DAMPs, while the impact of apoptosis may be presumably less significant here [36–39]. Today, it is widely accepted that DAMPs are the key predominant molecules which trigger the biological host response to trauma including SIRS, by activating and recruiting effector cells including antigen-presenting cells of the immune system [12, 40–46]. Thus, basically, every DAMP proven to promote efferent proinflammatory pathways can be considered to be involved in the development of SIRS. In 2012, in accordance with the newly recognized “sterile SIRS” as a severe complication form in polytraumatized patients, first clues to a critical role of DAMPs in the promotion of those hyperinflammatory responses have been reported [47]. Among those molecules, endogenous DAMPs including high-mobility group box (HMGB) protein 1, heat

shock proteins (HSPs), certain members of the S100A family, histones, free nucleic acids, members of the IL-1 cytokine as well as complement family as *bona fide* intracellular effectors, which upon abundant rapid release alert the environment about cell stress and danger, have already been reported to activate the posttraumatic innate immune responses and drive organ dysfunction(s) after trauma [12, 13, 46, 48].

Although a large number of endogenous nuclear or cytosolic DAMPs have been described in the context of the local/systemic posttraumatic and/or noninfectious “sterile” inflammatory response, which represents the key driver of the late occurring post-injury complications and fatal outcome rates, the knowledge on their variety and underlying mechanisms still remains unknown [49–51]. In particular, it is unknown whether there is a distinct pattern of DAMPs emission that may be helpful in differentiating between, i.e., sterile and infectious (bacterial or viral) sepsis form. The knowledge on posttraumatic DAMPs pattern may allow to further define the exact roles of DAMPs in hyperinflammation and develop therapeutic inhibitors targeting specific DAMPs to improve outcomes. Thus, some of most critically involved DAMPs in both sterile and infectious posttraumatic disorders will be briefly described in this review.

CARS and SAMPs

The recognition of an overshooting SIRS which may be associated with septic complications has provided several attractive targets for new anti-inflammatory drugs which were designed to prevent further propagation of inflammation in past. Yet, nowadays, treatment of sepsis in critically ill patients is mainly based on the prompt intravenous administration of adequate antimicrobial agents and support of organ functions. For the last four decades, in theory, many different targets for treatment were designed to inhibit, bind, or neutralize the proinflammatory mediators that were assumed to be responsible for the network of events that culminated in detrimental clinical outcomes. Disappointingly, however, targeted clinical trials have shown that most of these agents failed to cure the septic disease [52–56]. Even the promising US FDA-approved drug, recombinant human-activated protein C or drotrecogin- α failed in clinical trials and showed similar effects as placebo. Intriguingly, these observations paved the way to another typical symptomatic feature of the disorder: the CARS [24]. The high susceptibility to secondary infections after the initial phase of sepsis or after trauma has been attributable to CARS causing the posttraumatic IS [17, 19, 57]. Interestingly, for a long time, intensive care physicians have observed that patients with SIRS were prone to severe, sometimes lethal infectious

diseases. However, in search of the causes during the 1970s and 1980s, researchers found that many of those patients had acquired an impaired immune state characterized by various markers of IS. The concept was actually underlined from the beginning as the treatment strategies with anti-inflammatory agents failed in clinical trials on septic patients.

The phenomenon of impaired immunity that was frequently observed in posttraumatic as well as in septic conditions essentially reverses many of the typical events encountered in SIRS. However, research over the last several decades uncovered the anti-inflammatory and immunosuppressive mechanisms that govern the clinical post-injury disorders. Initially, IS corresponds to a homeostatic phenomenon to avoid the remote organ injuries caused by the early SIRS; however, it becomes deleterious when it persists, rendering patients prone to secondary infections [17, 58]. Nowadays, CARS is not regarded as part of a biphasic inflammatory response consisting of an initial SIRS with a subsequent CARS. It became evident that the hyper-resolving processes of inflammation (CARS, IS) occur nearly in parallel with the hyperinflammatory response, but also that they can exist separately from the SIRS [28, 59]. Moreover, CARS is not only a simplified anti-inflammatory process, but rather a disorder caused by a hyper-resolution of inflammation.

Remarkably, next to alterations of the innate immune system, posttraumatic IS has been closely linked to modulations of the adaptive immune system. Here, among others, i.e., a shift from a T-helper cell type (Th)1- to a Th2-mediated immune response, T cell anergy in traumatized patients, suppression of T cell effector functions, modulated frequency of T regulatory cells have been observed [19, 21, 22, 60–64]. This posttraumatic response suggests that in reverse with the proinflammatory action of DAMPs in SIRS, SAMP triggers the proresolving pathways in CARS and IS. Besides activating DAMPs, potentially suppressing DAMPs, that is SAMPs, are mainly produced by activated leukocytes and macrophages upon stress and injury, which—in parallel to proinflammatory responses, convey anti-inflammatory processes and shape immunosuppressive responses. In 2015, it was shown that the gene expression of proresolving lipid mediator pathways was closely associated with clinical outcomes in traumatized patients [65]. Patients with uncomplicated recoveries had differential and higher resolving scores [65]. The SAMPs prostaglandin E2 or AnxA1 plays significant roles in proresolving CARS [66–68]. Accordingly, DAMPs and SAMPs constitute valuable tools in diagnosis and therapy of severely injured and/or infected patients that are expected to find their way into clinical routine at the ICUs. Hyper-resolution with the following IS may be the most critical factor for the immune status of patients with either sterile or infectious SIRS. Thus,

here as well, measurement of DAMPs with their pattern, but also continuous determination of SAMPs with their pattern, respectively, may be used as hospital admission criteria for decisions supporting further diagnostic, prognostic, and therapeutic modalities. Although a closer look into both DAMPs and SAMPs is necessary to understand the post-traumatic response, in the underlying review only DAMPs will be addressed.

DAMPs

DAMPs are released from a damaged or diseased cell, and upon their release, they can stimulate a sterile immune or inflammatory response [13, 49, 69]. Across the tree of life, DAMP-induced immune responses serve as defense strategies aimed at maintaining and restoring homeostasis. However, despite their initially beneficial character, when dysregulated, uncontrolled, and exaggerated, the inflammatory and tissue repairing processes may become pathogenic and can lead to serious pathologies, i.e., sepsis, cardiovascular diseases, neurodegenerative diseases, diabetes, obesity, and asthma, as well as classic inflammatory diseases. Notably in the last two decades, the biological host response to trauma, which initially has been characterized by massive cytokine release as well as the activation and recruitment of effector cells including antigen-presenting cells, has further employed a large number of both microbial and host alarmins [12, 40–44]. In general, on the biochemical level, the posttraumatic immune response is not only activated by foreign non-self material, but includes also endogenous factors, DAMPs, which are released from necrotic or physiologically “stressed” cells, with the aim of initiating and recruiting effector cells of the immune system [70–72]. A large number of those endogenous nuclear or cytosolic triggers have been described to initiate and perpetuate the systemic posttraumatic and/or noninfectious inflammatory response; however, the knowledge on their precise role still remains unknown [13, 49–51]. They signal “danger” to the host and trigger an inflammatory response, which in physiological healing leads over to tissue regeneration, but when dysregulated can cause pathologic inflammation and related disorders.

In the pathology of severe trauma, trauma-induced generation/emission of DAMPs can refer to cell-intrinsic modified DAMPs such as cell-free deoxyribonucleic acid cfDNA or DAMPs passively released from dying cells. Thus, any kind of traumatic cell stress/tissue injury provoked by mechanical trauma (e.g., blow, crush, penetrating wound, or surgical procedures usually related to fracture, hemorrhage, and/or infections), thermal trauma, or metabolic trauma such as promoted by ischemia/reperfusion injury, acidosis, hypoxia/hypoxemia, provokes a DAMP release [23]. Clinically, SIRS is characterized by local and systemic release of

proinflammatory cytokines produced by DAMP-activated innate immune cells including IL-1 β , TNF, and IL-6, arachidonic acid metabolites, proteins of the contact phase and coagulation systems, and complement factors as well as hormonal mediators [3, 34, 73, 74]. Among other factors, proinflammatory cytokines also activate coagulation pathways, whereby enhanced thrombin formation increases fibrinogen cleavage and reduces fibrin monomers from polymerizing to form stable fibrin clots (hypercoagulability), which is why fibrinogen depletion is observed [75]. Disseminated intravascular coagulation (DIC) is a heterogeneous group of disorders, which manifests as a spectrum of hemorrhage and thrombosis complicating many primary conditions including, i.e., sepsis and trauma [76]. Although its pathophysiology is complex, there is growing evidence that DAMPs emitted in excess play a crucial role in the pathogenesis of DIC [76]. Here, i.e., cfDNA, also known as extracellular DNA, which can be released by various host cells including neutrophils, macrophages, eosinophils, and tumor cells, as well as by certain strains of bacteria plays a significant role [77–82]. Elevated levels of cfDNA have been found in various pathologic conditions including trauma [83, 84]. Interestingly, cfDNA that appears to exert both pro- and anti-fibrinolytic effects is a good predictor of trauma patient’s outcome in the ICU [84]. Activation of neutrophils with microbial or inflammatory stimuli results in the release of neutrophil extracellular traps (NETs) [77]. Upon cell death or specific cell activation of hematopoietic and parenchymal cells, extracellular cfDNA as well as DNA-binding proteins (e.g., histones and HMGB1) are released into circulation [13]. Those DNA-binding proteins are also strongly procoagulant and are involved in the pathogenesis of DIC [76, 85]. Another factor that can be directly influenced by DAMPs and contribute to DIC is the cellular migratory behavior with barrier loss. DAMP-induced endothelial expression of adhesion molecules facilitates leukocyte adhesion, promoting extravasation of leukocytes from the circulation into damaged tissue [86]. Mitochondrial (mt) DAMPs like mitochondrial DNA (mtDNA) and peptides appear in the blood after injury or shock, activate human leukocytes and might contribute to increased endothelial permeability during systemic inflammation [87]. The various DAMP motifs from mitochondria can act on endothelia and/or leukocytes via multiple pathways by enhancing leukocyte adherence to endothelial cells, activating cell–cell interactions, and subsequently increasing systemic endothelial permeability [87]. Mitochondrial DAMPs may be important therapeutic targets in conditions where inflammation pathologically increases endothelial permeability [87]. The mechanisms of a concerted action between endothelial cells and leukocytes, endothelial cell damage, leukocytes extravasation, microcirculatory disturbances, or DIC frequently lead to cell loss of parenchymal cells with the following organ failure. Increased

systemic levels of DAMPs have been positively correlated with mortality and morbidity of patients or animals with trauma or surgical insults, while blocking or neutralizing DAMPs with specific small molecules or antibodies ameliorated sepsis and SOF *in vivo* [88]. As briefly introduced above, the clinical manifestation of severe multiple tissue injury including burn damage is characterized by a systemic cytokine/chemokine-induced hyperinflammatory response resulting in SIRS which is accomplished by an intense and long-lasting CARS associated with posttraumatic immunosuppression that predisposes patients to infectious sepsis and MOF [3, 17, 19, 57]. For example, in a murine burn injury model, IL-10 levels were significantly increased at 24 h, 7 days, and 21 days post-injury as compared with IL-10 levels in sham mice [89]. Thus, accumulating evidence suggests that clinically observed infectious complications are associated with high susceptibility of the patient to secondary bacterial, fungal, and viral infections and that this state is mediated by suppressing DAMPs by SAMPs which control homeostasis following injury. Yet, in the following, a closer look at the role of exemplary DAMPs in traumatic setting is taken. Since DAMPs are a culmination of highly heterogeneous mediators, it is nearly impossible to choose the most important ones. Thus, in this review, we focus on the most prominent DAMPs involved in the posttraumatic pathophysiology, but other DAMPs of equal importance, which have been neglected here, may be addressed in further studies. This review sought to primarily describe the exemplary variety of DAMPs in their preclinical and clinical context.

High-mobility group box protein

HMGB1 as one of best studied DAMPs is a non-histone chromatin nuclear peptide that acts as a DNA chaperon, which is involved in binding of proteins and in DNA transcription, replication, but also repair [90, 91]. HMGB1 is composed of two positively charged DNA-binding motifs and a C-terminal acidic tail [92]. Nearby, all cells constitutively express HMGB1. It is located in the nucleus, but it will be released either passively after necrotic cell death, or secreted actively by living cells undergoing stress in response to angiogenic and inflammatory triggers [93–96]. HMGB1 acts as an endogenous ligand of toll-like receptors (TLRs) 2, 4, 9 and receptor for advanced glycation end products (RAGE), thereby inducing nuclear factor “kappa-light-chain-enhancer” of activated B cells (NF- κ B) activation [97, 98]. Although the mechanisms of HMGB1 secretion are elusive, it has been shown that its processing via inflammasomes is involved [99].

The innate immune stimulatory activity of HMGB1 has been regulated by the redox state of cysteine residues C23, C45, and C106 [100]. Interestingly, while a reduction in

cysteine residues makes HMGB1 rather a chemoattractant than a cytokine inducer, oxidization of the cysteine residues via reactive oxygen species abrogates both activities of HMGB1 [101]. Thus, it remains elusive, if HMGB1 levels indeed reflect its innate immunity-inducing potential, since the HMGB1 levels do not necessarily reflect the complexity of inflammatory complications with underlying downstream signaling.

Under physiological conditions, HMGB1 is predominantly anchored inside the nucleus via nuclear localization sites and accordingly its binding with nuclear cargo carrier proteins [102, 103]. Systemic levels of HMGB1 increased within 30 min after severe trauma in patients [104] although its regulated activity HMGB1 levels correlated with injury severity, tissue hypoperfusion, early posttraumatic coagulopathy, hyperfibrinolysis, with complement activation and with SIRS [104]. Early increase in systemic HMGB1 levels indicated patients who developed acute lung injury (ALI) or acute renal failure in the later posttraumatic course [104]. Increased levels of HMGB1 were found to stratify non-survivors from trauma as compared to survivors [104]. Deng et al. [103, 105] have recently demonstrated that hepatocytes are the main source of circulating HMGB1 in LPS-induced endotoxemia and cecal ligation and puncture (CLP)-induced polymicrobial sepsis, as well as hemorrhagic shock. They have demonstrated that cell-specific depletion of HMGB1 in hepatocytes dramatically reduced circulating HMGB1 level and conferred protection from sepsis lethality in mice [105]. With regard to trauma, Levy et al. [106] have demonstrated transient elevations in systemic HMGB1 levels within 1 h post bilateral femur fracture. Interestingly, they have shown that after trauma, treatment with neutralizing antibodies to HMGB1 lowered systemic IL-6 and IL-10 levels as compared to controls treated with nonimmune control antibody [106]. Similarly to the above-mentioned study, with regard to hepatic changes, HMGB1 neutralization decreased serum alanine aminotransferase levels, and hepatic as well as gut mucosal NF- κ B DNA binding [106]. The authors conclude that HMGB1, more precisely the TLR4-HMGB1 pathway, constitutes as an early mediator of systemic inflammation and end-organ injury after peripheral tissue injury after trauma. In line with these observations, it has been demonstrated *in vivo* that HMGB1 levels significantly increased in muscle 12 h after crush injury [107]. As already indicated, HMGB1 neutralization by an antibody reduced the cellular apoptosis in the renal cortex, thus indicating a positive feedback cycle [107]. In a systematic review on the role of HMGB1 danger signaling in TBI, HMGB1 was found to be released from damaged neurons, and furthermore, it was elevated in patient’s serum and cerebrospinal fluid (CSF) [108]. Moreover, HMGB1 increased in CSF associated with neuronal death in subarachnoid hemorrhage [109, 110]. The elaborated studies show that HMGB1 may serve as a

prognostic biomarker and therapeutic target in patients with TBI [108]. Adjacent to traumatic injury, it was demonstrated before that HMGB1 plays an important role in the initiation and propagation of inflammation and organ injury under conditions of sterile inflammation which involve ischemic processes [111–113]. Also in patients with ventilator-associated pneumonia during mechanical ventilation increased HMGB1 levels in bronchoalveolar lavage fluid (BAL) were detected [114]. In vivo models have demonstrated that intratracheal or intranasal administration of HMGB1 caused ALI, which has been reflected by enhanced acute inflammatory injury to the lungs, neutrophil accumulation, development of lung edema, and increased pulmonary production of IL-1 β , TNF α , and macrophage-inflammatory protein (MIP)-2 [115, 116]. Also in different ischemic heart diseases a positive correlation between increased HMGB1 levels and worsen ventricular function upon ischemia/reperfusion injury has been demonstrated [117]. As briefly described in Introduction, DAMPs are playing a role in coagulation processes. HMGB1 itself is also a potent procoagulant that can directly stimulate and recruit platelets through TLR4 and RAGE [88, 118, 119]. Mice with HMGB1-deficient platelets exhibited increased bleeding times and reduced thrombus formation, platelet aggregation, inflammation, and organ damage during experimental trauma/hemorrhagic shock [118]. Extracellular HMGB1 coordinates numerous cellular functions, including migration, chemotaxis, activation, maturation, and proliferation but also the redox status of its target cells [120–123]. However, the binding of HMGB1 to its receptors can be potentiated by binding to a whole variety of other factors, including PAMP and cytokines [123]. Thus, in summary, HMGB1 is an important pathogenic factor of inflammatory and thrombotic complications.

Interleukin-1

Some of the numerous DAMPs are cytokines, small messenger molecules, which are produced, activated, and released upon trauma [124]. In 1974, Dinarello [125] discovered the first cytokines IL-1 α and IL-1 β as members of the IL-1 family. IL-1 α and IL-1 β are encoded by different genes; however, they can be bound by the same IL-1 receptor (IL-1R) [125]. IL-1 α has a higher affinity for IL-1R1 and IL-1 β for the soluble IL-1R2 [126].

In contrast to IL-1 β , IL-1 α is constitutively expressed mainly in resting nonhematopoietic cells, which line the gastrointestinal tract, liver, kidney, and skin, but it can also be expressed in most cells and, furthermore, can be biologically active in its full-length form without its previous processing through inflammasomes, as it is mandatory for IL-1 β activity [127–129]. IL-1 α and IL-33 are expressed in their precursor forms in the nucleus of various hematopoietic cells, and these nuclear proteins play important roles in

the regulation of gene expression [130]. Since IL-1 α does not contain a secretory signal peptide, it is released into extracellular space through either non-canonical vesicular secretion pathway or passive necrotic release [130]. The release of IL-1 α into the extracellular space in stimulated cells occurs after processing of the membrane-bound IL-1 α by the membrane-bound calcium-dependent cysteine protease calpain [130–133]. Upon extracellular IL-1 α interaction with ubiquitously expressed IL-1R1 and IL-1 receptor accessory protein downstream signaling proteins, such as myeloid differentiation primary response gene 88 (MyD88) and IL-1 receptor-activated protein kinase 4, an inflammatory response is induced [134]. In general, members of the IL-1 family induce similar signaling cascades in their target cells via mitogen-activated protein kinase (MAPK) or NF- κ B pathways [135]. IL-1 α as a dual function protein is a proinflammatory activator of transcription as chromatin-associated protein, and above that, it is acting as a cytokine [136–138]. The latter is exerting its function after being released from apoptotic or necrotic cells, thereby alerting the immune system to tissue damage [139].

Thus, IL-1 α has been considered a potential pathogenic factor involved in the development and progression of several disease including diabetes, inflammatory bowel disease, myocardial inflammation, and cancer [140–143]. Interleukin-1 can initiate many important immunological responses such as fever, prostaglandin synthesis, mobilization of neutrophils into tissues, activation of B and T cell lymphocytes, fibroblast proliferation as well as the production of antibodies, collagen, and cytokines [126, 127]. With regard to trauma, only few studies on IL-1 α are available. Jackman et al. [144] observed a mixed early systemic inflammatory response in trauma patients with elevated levels of IL-6, IL-10, IL-1Ra, macrophage migration inhibitory factor, myeloperoxidase (MPO), monocyte chemotactic protein-1, matrix metalloproteinase-9, and soluble Fas ligand, but also with simultaneously decreased levels of fractalkine, epidermal growth factor, IL-7, IL-9, IL-17, TNFbeta (TNF β), MIP-1 α , macrophage-derived chemokine and notably IL-1 α . While in vivo DNA microarray data confirmed this highly complex inflammatory response in lung tissue following blunt chest trauma, interestingly, IL-1 α has shown elevated expression levels, which were concomitant with increased levels of other inflammatory and coagulatory proteins, including TNF α receptor, IL-1 β , C3, NF- κ B, and plasminogen activator [145]. In contrast to the above-mentioned study, increased levels of IL-1 have been associated with the pathogenesis of acute respiratory distress syndrome (ARDS), and subsequent idiopathic pulmonary fibrosis, sarcoidosis, as well as certain other inflammatory diseases [130, 146]. Notably alveolar macrophages (AM) from patients with ARDS were shown to release significantly more IL-1 and IL-1 β as compared with controls, indicating

that increased IL-1 release by AM may be related to the progression of ALI [146]. Also inflammation caused by necrosis or tissue damage upon ischemia or hypoxia caused by poor oxygen supply has been related to IL-1 [130]. Hypoxia upregulated IL-1 α transcription in epithelial cells [147]. Ischemia induced IL-1 α release in activated platelets of the brain vasculature, and thereby stimulated endothelial cells to secrete the chemokine CXCL1 and express cell adhesion proteins vascular cell adhesion molecule-1 and intercellular adhesion molecule-1, thus promoting the transendothelial migration of neutrophils which are major contributors to inflammation-mediated brain injury [148]. IL-1 α -stimulated proinflammatory cytokine expression in necrotic myocytes from ischemic heart following myocardial infarction has been reported as well [149]. It is known that IL-1 α is a significant driver of the proinflammatory mechanisms, which are often linked to chronic inflammatory diseases or cancer [130]. However, only little is known about the role of IL-1 α during the post-injury inflammatory response. Thus, uncovering its role in trauma and/or trauma-related pathologies may be promising in regard to specific targeting of IL-1 α with clinically approved drugs, i.e., anakinra under pathological conditions.

Interleukin-33

Interleukin-33, a nuclear alarmin, is the youngest member of the IL-1 family, and it is mainly expressed in the cells which are in contact with the environment including stromal cells, such as endothelial cells, fibroblasts, and epithelial cells [130, 150, 151]. Thus, IL-33 is highly expressed in the lungs of both mice and humans [152]. Similar to IL-1 α , IL-33 can be released upon the loss of cell integrity [153, 154]. Upon binding to its orphan receptor serum stimulation (ST)2 of the TLR/IL1R superfamily of receptors (also known as IL-1RL1), IL-33 initiates the potential signaling pathway via NF- κ B and MyD88 [155, 156]. Interestingly, regulatory T cells that express the IL-33 receptor, ST2, upregulate amphiregulin after IL-33 stimulation, and this mechanism has been implicated recently in epithelial tissue repair after viral infection of the lung [157]. Again similar to IL-1 α , IL-33 does not require processing to maintain its activity [158]. However, IL-33 can be cleaved to a mature and more proinflammatory form [159]. Interestingly, unlike other DAMPs, i.e., HMGB1 and IL-1 α , nuclear IL-33 represses gene expression, and its nuclear localization alters the subcellular localization of IL-33, thereby regulating its extracellular functions and affecting immune homeostasis [160, 161]. On the other hand, comparable to other alarmins, posttranslational modification of IL-33 via its oxidation can regulate its activity, and thereby restrict its inflammatory function to the local environment [130, 162]. IL-33 plays an important role in inflammatory and autoimmune diseases

such as asthma, inflammatory bowel disease, or autoimmune hepatitis by influencing neutrophilic infiltration into tissues, modulating the type 2 immune response, including Th2 cells, mast cells, eosinophils, basophils, and group 2 innate lymphoid cells [158, 163–166]. The relevance of IL-33 processing in a pathological environment is still not clear, but it is evident that an inflammatory microenvironment can exacerbate disease-associated functions of IL-33 via generating more active mature form [159].

Recently, Liu et al. [167] have shown that the sensitivity of IL-33-deficient mice to bleomycin-induced ALI and that this phenotype was reversible by complementation with rIL-33. The authors conclude that IL-33 is a crucial local factor necessary to control and limit the early inflammatory response after chemically induced ALI [167]. On the other hand, depending on the context of certain infections, IL-33 was either protective or even deleterious, because of its either beneficial role in the resolution of inflammatory processes, or detrimental function in aggravating inflammation [130, 154, 168]. Interestingly, IL-33 reduced mortality in septic mice due to increased neutrophil influx into the peritoneal cavity and thereby enhanced bacterial clearance as compared to controls [169]. The data are significant, since they show that IL-33 reduced systemic but not local proinflammatory responses, and thereby limited the sepsis-induced systemic inflammation [169]. Under certain conditions of chronic inflammation, IL-33 was deleterious during the development of, e.g., asthma, or in the context of chronic obstructive pulmonary disease (COPD) and arthritic joint inflammation [170–172]. The role of IL-33 in traumatic setting is completely elusive. However, there are some studies dealing with IL-33 during injury to the central nervous system (CNS) or spinal cord. It has been shown that IL-33 was highly expressed in white matter in the CNS, where it colocalized with oligodendrocyte markers as well as with astrocyte markers in gray matter [173]. Immediately after CNS injury IL-33 was released from damaged oligodendrocytes, acting on local astrocytes and microglia to induce chemokines critical for monocyte recruitment [173]. Mice lacking IL-33 had impaired recovery after CNS injury, which is associated with reduced myeloid cell infiltrates and decreased induction of M2 genes at the injury site [173]. Wicher et al. (2017) used samples from human TBI microdialysate, tissue sections from human TBI, and mouse models of central nervous system injury and found that expression of IL-33 in the brain was elevated from nondetectable levels, reaching a maximum after 72 h in both human samples and mouse models [174]. The authors have shown that astrocytes and oligodendrocytes were the main producers of IL-33 [174]. Post-TBI brains of mice deficient in the IL-33 receptor, ST2, contained fewer microglia/macrophages in the injured region as compared to the wild-type controls and had an altered cytokine/chemokine profile in response

to injury [174]. Taken together, these observations indicate that IL-33 plays a role in neuroinflammation with microglia/macrophages being cellular targets for this interleukin post-TBI. Other *in vivo* experiments have shown before that after traumatic spinal cord injury (SCI) administration of recombinant IL-33 turned beneficial by significantly decreasing tissue loss, demyelination and astrogliosis in the contused mouse spinal cord, finally resulting in dramatically improved functional recovery [175]. Taken together, the recent findings indicate that IL-33 plays a role in response to TBI and drives chemokines that recruit monocytes and polarize macrophages toward an M2 phenotype, thereby potentially protecting neurons from further damage and promoting recovery after CNS injury [176]. Maybe a role of IL-33 as a potential SAMP should be carefully considered.

S100A proteins

S100 proteins or calgranulins are a family of low molecular weight calcium-binding homodimeric proteins, consisting of at least 25 distinct members with a large variety of intracellular and/or extracellular functions [130]. They are localized intracellularly in the cytoplasm, and here, they interact with various effector molecules to regulate cell proliferation, differentiation, migration, energy metabolism, scavenging of reactive oxygen species (ROS) and nitric oxide, calcium homeostasis, inflammation, apoptosis, transcriptional regulation as well as DNA repair and others [16, 130]. S100 proteins are mainly expressed in cells of myeloid origin, predominantly in neutrophils and are induced in several cell types which mediate inflammatory responses and recruit inflammatory cells to sites of tissue damage [177]. These small proteins are known to be either passively released from damaged cells or actively secreted from activated cells, and they have been detected in various body fluids, such as serum, urine, sputum, cerebrospinal fluid, and feces of patients with cancer, inflammatory and autoimmune disease, or cardiovascular complications, atherosclerosis or stroke [130, 178–183]. Upon their release, they act as alarmins via their interaction with different receptors to orchestrate innate and adaptive immune responses [130, 184]. As example, S100A8, S100A9, and S100A12 family have been found extracellularly at high concentrations in inflamed tissue, where they exert their proinflammatory effects via binding to RAGE, TLR4 or upon interaction with other receptors [177, 185]. The signaling pathways trigger the activation of kinases including p38 MAPK, ERK1/2, and again transcription factor NF- κ B [186–188]. S100A1 released from damaged cardiomyocytes during myocardial infarction triggers TLR4-dependent proinflammatory responses, leading to induction of myocardial damage [189]. Several studies have reported an increase in S100A8/A9 levels in sepsis [190–192]. However, certain anti-inflammatory properties

in case of, e.g., S100A8 and S100A9 have been reported as well [193, 194].

With specific regard to traumatic injury, it has been demonstrated that S100B in CSF and plasma increases after injury and, even more, that the increasing levels were negatively correlated to outcome from human TBI [195–197]. It was shown that S100B can counteract and reduce some negative cellular consequences of injury [184, 196, 198]. However, more recent studies imply the negative role of S100B in TBI and represent that S100B in CSF, as an astrocytic protein specific to the central nervous system and a useful marker in outcome prediction for TBI [199, 200]. Thus, S100 s protein have been established as useful marker for inflammatory diseases and blood brain barrier damage, which plays an important role in the development and recovery of normal CNS after injury [201–203]. Recently, results of a meta-analysis showed a significant difference in S100B levels between survived and died subjects with head injuries on overall follow-up timeline, during treatment, or 6 months with an average threshold value that varies according to the study method used [203]. In terms of other S100 proteins and nervous injury, following peripheral nerve injury an immediate acute immune response distally and proximally to the lesion site with rapid transcriptional activation of S100a8 and S100a9 genes resulting in S100A8/A9 hetero- and homodimers has been observed [204]. The subsequently provoked release of chemokines and cytokines by activated Schwann cells induced an initial chemotactic gradient, which was responsible for the transmigration of hematogenous immune cells toward the traumatized site of the injured nerve [204]. Also after severe burn injury, S100A8 and S100A9 levels in bloodstream were correlated with poor outcome [205]. These proteins were found to be increased in a biphasic manner with the early peak at initial presentation representing the innate response to injury [205]. Similar to HMGB1, S100A8 and S100A9 levels in the bloodstream increase early in the acute phase of trauma or brain injury. Thus, although large number of studies deals with neurological trauma, there is some evidence that other S100 protein, i.e., S100B is also elevated in patients with major extracranial trauma [203, 206–208]. S100B concentrations upon admission correlated positively with injury severity and decreased survival in major trauma patients, observations which were independent of head injury [206, 208]. In general, circulating levels of S100B in severely injured trauma patients were increased as compared to healthy volunteers [206]. Even more, S100B levels correlated with systemic levels of sE-selectin and von willebrand factor, which are indicating endothelial cell injury [206, 209]. Further mechanistical analyses of human endothelial cells transfected with S100B uncovered an increase in apoptosis and levels of proinflammatory cytokines IL-6 and IL-8 [206]. Thus, S100B apparently correlates with endothelial

damage indicating important pathomechanistical influence of S100B in the recovery from trauma. However, it cannot be ruled out that increased S100B after soft tissue trauma might occur due to peripheral nerve injury. On the other hand, currently a protective role of certain members of the S100 family as briefly addressed above cannot be ruled out. Notably in a study on human trauma victims, human blunt trauma survivors were seen to produce higher levels of S100A8 and S100A9 than non-survivors, and a preliminary screen suggested that interferon- γ inducible protein 10 (CXCL10) was significantly increased in monocytes/macrophages stimulated with S100A8/S100A9 [210]. Thus, heat shock protein (HSP)70, S100A8/S100A9 DAMPs appear to exert a protective role after trauma. This remains to be further elucidated in future.

Histones

Other critical members of DAMPs are the circulating extracellular histones which act as clinically relevant mediators of multiple organ injuries [211, 212]. These nucleoproteins enable DNA compaction into nucleosomes, thereby contributing to the structural organization and stability of chromatin. As they localize in the nucleus, their release into the extracellular space, as free histones, DNA-bound histones (nucleosomes), or part of NETs, has been recently recognized as candidate of the DAMP family, and as such in all three forms, they can be detected in serum after significant cellular death which is occurring in infective or sterile SIRS [213, 214]. Their extracellular activity has a long history, while more than 50 years ago the first observations uncovered the antibacterial potential of these molecules [215, 216]. Since Xu et al. [217] have demonstrated that extracellular histones released in response to inflammatory challenge contributed to endothelial dysfunction, organ failure and death during sepsis, the mechanisms of histone-mediated injury in certain organs have been extensively studied. Clinically, elevated levels of circulating histones and histone–DNA complexes were associated with the incidence of MOF, disseminated intravascular coagulation, cardiac injury, arrhythmia, and ventricular dysfunction in patients with sepsis [218, 219]. Therefore, the extracellular histone also acts as an immunothrombotic agent. Furthermore, pharmacological targeting by antibodies to histones or by activated protein C (APC) reduced the mortality of septic mice [217]. Thus, the authors proposed extracellular histones as potential molecular targets for therapeutical treatment of sepsis and other inflammatory diseases.

Pathomechanistically, histone administration resulted in neutrophil margination, vacuolated endothelium, intra-alveolar hemorrhage and macro- and microvascular thrombosis in vivo [217]. Histones mainly bind and activate TLR, e.g., TLR2, TLR4 or TLR9 on various cells, and similar to

other DAMP, they subsequently trigger the inflammatory response [213, 220, 221]. This has been confirmed in vivo, by showing that histone administration led to death after a dose-dependent aggravation of multiple organ injury in mice [211]. The causative effects for organ injuries were histone-driven endothelial damage, and the associated release of HMGB1 [211]. The authors concluded that extracellular histones induce multiple organ injury in two progressive stages via direct endothelia disruption, and the subsequent release of other DAMPs [211]. Circulating levels of histones were significantly increased after severe non-thoracic blunt trauma in patients [222]. Furthermore, enhanced histone levels positively correlated with severe complications such as the incidence of ALI, and dismal prognosis, as well as with markers of endothelial damage and coagulation activation [222]. The harmful impact of histones on endothelia has been confirmed in vitro and in vivo demonstrating that histones directly damaged endothelial cells, stimulated cytokine release (e.g., TNF α , IL-6, and IL-10), induced NET formation and MPO release [222]. An anti-histone antibody reduced the harmful changes and protected mice from histone-induced lethality [222]. Also in a large in vivo model of polytrauma, increased extracellular histone levels could have been linked to cardiac dysfunction after porcine multiple trauma [223]. Thus, histone release plays an important pathological role in trauma-associated injuries [222, 223].

Heat shock proteins

So far, only a few studies have investigated the relation of HSP to trauma-induced tissue damage [224]. Heat shock or stress response is a highly preserved cell response to injury which is actually a cell defense mechanism characterized by an increased expression of heat shock or stress proteins. HSP constitutes a group of proteins that primarily act as molecular chaperones in the cytosol which are constitutively expressed by all cells. HSPs are essential for significant cell processes such as protein folding, protein protection from denaturation or aggregation, and facilitation of protein transport through membrane channels [225, 226]. Thus, their specific elevated expression during the heat shock response stands for their essential role in protecting cells from stress, and preparing them to survive under environmental challenges [227]. HSPs are induced by a variety of cellular stress factors, including hypo- and hyperthermia, UV radiation, pathogens, and other forms of stress [16, 227, 228]. HSP family members are named according to their molecular mass [229]. Although HSPs were considered for some time as intracellular molecules that could only be released from necrotic cells by a passive mechanism [230], meanwhile it is known that they may be released by non-necrotic cells via an active mechanism including the non-classic protein release pathway, through which HSPs are released both as

free proteins and within highly immunogenic exosomes [231]. It has been under discussion, if HSP in general constitute DAMPs, or if the most widely studied HSP70 is rather an exception [224]. This is not easy to evaluate since very often contamination with immunogenic molecules, i.e., LPS or DNA, can generate false-positive responses and results.

Upon release, HSP70 can stimulate monocytes/macrophages, microglia, and dendritic cells via the TLR2 and 4 and cluster of differentiation (CD)14 pathways, subsequently leading to the activation of intracellular signaling pathways [229]. Next to TLR, HSP70 binds to CD36, CD40, CD91, siglec-5, and siglec-14, lectin-like oxidized low-density lipoprotein receptor 1, and scavenger receptor class A to induce pro- or anti-inflammatory responses on a range of cells, mainly those of the innate immune system with exception of T lymphocytes [232–234]. Notably in studies of cerebral ischemia, neurodegenerative diseases, and epilepsy, HSP70 reduces protein aggregates, intracellular inclusions, and apoptosis improving neurological outcomes [229, 235–237]. However, conflictive results are found regarding HSP functions. On the one hand increased levels of HSP27, HSP60, HSP70, and HSP90 in patients with infectious septic complications [238–240], and significant improvement in mortality, lung function, local and systemic inflammation in a mouse model of severe sepsis-induced ALI after therapeutic HSP90 inhibition have been observed [241]. On the other hand, in a CLP-induced sepsis model in HSP70.1/3 knockout mice, NF- κ B binding/activation, TNF α and IL-6 in lungs and mortality were increased [242]. Thus, HSP70 may confer protection from ARDS via acting at least partly through the NF- κ B pathway and thereby reducing the proinflammatory cytokine response [242]. In line with these observations, HSP70 played a protective role in an age-dependent response to sepsis by preventing excessive gut apoptosis and both pulmonary and systemic inflammation [243]. Thus, multiple data are available suggesting that HSP are potent regulators of inflammatory events.

Severe trauma causes enhanced expression of HSP in polymorphonuclear leukocytes (PMNL) during the acute post-injury phase [244]. In comparison with healthy volunteers increased expressions of HSP27, HSP60, HSP70, and HSP90 in PMNL from trauma patients or patients with burn trauma were found, indicating that this enhanced expression of HSP may regulate PMNL functions [244, 245]. Concomitant with these changes was an increase in oxidative activity in PMNL, and markedly inhibited cell apoptosis after thermal injury [245]. Extracellular HSP60 release was observed within 30 min after trauma and correlated with the development of ALI [246]. Extracellular HSP have powerful immune properties by activating the classical complement pathway, participating in exogenous antigen processing and presentation, and showing immune reactivity to endogenous HSP [247]. Thus, HSP can also have an immunostimulatory

effect and activate the host inflammatory response [224]. In mechanistical in vitro studies, it was shown that HSP60 caused the release of nitric oxide by macrophages [246]. Taken together with previously described in vivo observations, the authors suggest that the extracellular release of the immature HSP60 may be associated with traumatic cell necrosis, and could be involved in the release of NO by immune competent cells, subsequently inducing an activation of the local inflammatory response [246]. Similarly, systemic HSP72 levels were markedly elevated immediately after admission of severely traumatized patients to the emergency department as compared to healthy volunteers [248]. Interestingly, elevated initial HSP72 levels were associated with improved survival in severely traumatized patients, without showing any association to the overall injury severity [248]. Notably concerning HSP72 conflictive reports are shown. Pittet et al. [248] reported that HSP72 was neither related to the incidence or severity of the inflammatory response nor to post-injury organ dysfunction.

HSP70 serum concentrations have been up to ten times higher immediately after injury in polytraumatized patients versus control subjects, levels that remained elevated until 48 h after the accident following a time kinetics concordant with that previously described [75, 248]. The magnitude of this increase was related to injury severity and prediction of secondary infection [249]. If HSP70 levels decreased in the period from 60 to 90 h after trauma, the patient had a better outcome as compared to those patients without a decrease in HSP70 levels [249]. The high extracellular concentration of HSP70 was even greater in patients with MODS [224]. Although the authors did not include follow-up of survival after hospital discharge and all patients except one survived during admission, the greater elevation of extracellular HSP70 in patients with MODS corroborates the proinflammatory character of this protein in severe trauma as reported by others as well, who also correlated HSP70 with survival and morbidity [250, 251]. In summary, these data support the hypothesis that HSP70 is produced as a danger signal to stimulate the immune systems of trauma patients [224, 252].

Nucleic acids

All human cells contain nucleic acids as deoxy nucleic acid (DNA), messenger ribonucleic acid (RNA), or mtDNA while mature erythrocytes may also retain some residual non-functional mtDNA [253, 254]. The endosymbiotic theory suggesting that mitochondria originate from bacteria, provide the cellular content of mtDNA. Usually, nucleic acids are released into the circulation after cell necrosis and nuclear destruction, but their active release has been reported as well [16, 255, 256]. This so-called extracellular cfDNA can be built up by either DNA or different species of RNA, and based on its origin, whether it is host or pathogen

derived, it accounts for a DAMP or a PAMP, respectively [255]. TLRs are evolutionary conserved pattern recognition receptors (PRR) for detection of multiple microbial products including bacterial DNA and RNA, sense invading microbes and initiate a rapid immune response [257, 258]. However, adjacent to membrane-bound TLR3, TLR7, TLR8, TLR9, and RAGE, soluble mainly cytosolic receptors retinoic acid-inducible gene I, melanoma differentiation-associated protein 5, and cyclic guanosine monophosphate-adenosine monophosphate can recognize the cfDNA signals [255, 259, 260]. Intracellular mechanisms of mtDNA inflammation include inflammasome activation and stimulator of interferon gene pathway activation [261]. However, although these mechanisms have not been confirmed directly in the trauma setting, based on available scientific research plausible mechanisms exist [262]. The cfDNA released from mammalian cells and bacteria is a potent stimulator of the innate immunity. The ability of the cell to distinguish dangerous nucleic acids from safe counterparts may be determined by the unique cellular location of nucleic acid-sensing PRR [263–265]. In addition to proinflammatory activity, elevated plasma DNA and mtDNA as well as nDNA in patients with pulmonary embolism as compared to those patients with submassive pulmonary embolism or other diagnoses (pneumonia, myocardial infarction, thrombophlebitis, or normal lung scans) suggest that cfDNA may induce potent prothrombotic effects as well [266, 267]. NETs, which constitute a meshwork of DNA fibers comprising histones and antimicrobial proteins, stimulated thrombus formation both in vitro and in vivo, while the treatment with deoxyribonuclease (DNase) or anticoagulant heparin prevented NET-mediated thrombus formation [268]. Thus, cfDNA acts as potent immunothrombotic agents [265]. Increased levels of cfDNA in the form of nuclear DNA (nDNA), mtDNA, or NETs were found and correlated with detrimental outcomes in patients with sepsis [269, 270], cancer [271], autoimmune disease [272], cardiopulmonary bypass surgery [273], and solid organ transplantation [274].

As recently reviewed by Thurairajah et al. [262], clinicians have regarded DNA and mitochondria as intracellular structures, unrelated to the pathophysiology of trauma. Meanwhile, we are beginning to understand the large impact of cfDNA on posttraumatic inflammation. Release of cfDNA plays an important role in trauma [84, 256]. The group around Hauser [256] has shown that traumatic injury causes a release of mtDAMPs into the circulation, which have functionally important immune consequences. These DAMPs include formyl peptides and mtDNA as well, which can activate human polymorphonuclear neutrophils via TLR [256]. Briefly, tissue injury caused by trauma results in uncontrolled rupture of cell membranes and cell contents are spilled into the extracellular space [275, 276]. Adjacent to the release of mtDNA, numerous other DAMPs and ROS

from damaged neighboring cells promote further necrosis and mtDNA release [50, 277]. As observed in traumatized patients, cf-mtDNA concentration positively correlated with injury severity, incidence of SIRS, and mortality [278–281]. Plasma levels of DNA were increased concomitant with the injury severity caused by trauma, and the concentration of mtDNA correlated not only with SIRS but also with the occurrence of ALI and MODS [256, 278, 280–282]. In vivo studies confirmed that hemorrhagic shock and trauma raised plasma mtDNA concentration [283]. The raised mtDNA concentration persisted throughout the 7 days of sampling. Not only traumatic insults but also surgical interventions result in tissue injury and can also increase cf-mtDNA release [284]. Also upon femoral reaming or cardiopulmonary bypass surgery, high quantities of mtDAMPs were identified [285]. Even more, the higher concentrations of mtDNA correlated with postoperative complications [273]. Interestingly, endotracheal tube placement in surgery has been associated with higher concentrations of mtDNA in throat lavage fluid, and a correlation between non-infected sore throat post-intubation and elevated throat lavage mtDNA concentration was found [286]. Although it appears that the inflammatory effects of mtDNA can be beneficial and harmful, in the trauma setting, the increase in cf-mtDNA associated with MOF proposes rather a harmful scenario of mtDNA-induced inflammation [80, 278, 287]. Interestingly, Prikhodko et al. [288] have demonstrated that the levels of circulating mtDNA significantly increased in trauma patients compared to those in healthy volunteers, but that purified mtDNA could not stimulate innate immune cells. These data suggest that the level of extracellular DNA in the blood may be a suboptimal marker for human disease. Development of new approaches to detect circulating extracellular DNA that actually activates innate immune cells would be beneficial. Although enormous research and efforts to develop therapeutic agents that neutralize cf-mtDNA are ongoing, there is still insufficient knowledge to including this into clinical management. Current goals are limited to the validation of cf-mtDNA as a biomarker of injury severity, and/or predictor of SIRS/MOF to improve the clinical management of patients.

Adenosine triphosphate

Adenosine 5' triphosphate (ATP), another DAMP originating from mitochondria, can be released passively due to tissue damage or actively via channels or vesicular exocytosis, contributing to the induction of inflammation by activation and recruitment of various inflammatory cells, e.g., macrophages, neutrophils, and dendritic cells [46, 50, 289–293]. Stimulation of virtually any mammalian cell type leads to the release of cellular ATP and autocrine feedback through a diverse set of different

purinergic receptors [294]. Extracellular ATP signaling is transduced, e.g., via the purinergic receptor P2X7 with subsequent efflux of potassium ions, with following aggregation and activation of inflammasomes [290, 291, 294]. Thus, ATP gating of P2X7R with the subsequent assembly of the NLRP3 inflammasome/caspase-1 complex is critical for IL-1 β maturation as well as its release [295]. Human neutrophils, which play an important role in tissue damage and repair, release ATP from the leading edge of the cell surface to amplify chemotactic signals and direct cell orientation and migration by feedback through P2Y2 nucleotide receptors [293, 296]. Thus, ATP release and autocrine feedback through P2Y2 and A3 receptors provide signal amplification, controlling gradient sensing and migration of neutrophils [293]. It was shown that systemic ATP impairs polymorphonuclear neutrophil functions by disrupting the endogenous purinergic signaling mechanisms that regulate cell activation and chemotaxis [297]. Based on their data, the authors suggest that removal of systemic ATP improves polymorphonuclear neutrophil function and host defenses, making this a promising new treatment strategy for sepsis [297].

In case of, e.g., overaggressive mechanical ventilation strategies, direct injury or cyclic deformation can release massive amounts of extracellular ATP from type I alveolar epithelial cells [298]. High levels of ATP may saturate ATP degradation resulting in increased alveolar ATP levels despite the ongoing enzymatic conversion to the immunosuppressive purine, adenosine [298]. The authors suggest that this sequence of events may be an important contributor to both pneumonia and clinical ALI.

Complement factors

Exposure to traumatic or infectious insults results in an immediate activation of the complement cascade as major fluid defense system of innate immunity [48, 299]. As nicely described by Huber-Lang, the complement system acts as a master alarm system during the molecular danger response after trauma and significantly contributes to the clearance of DAMPs and PAMPs [48, 299]. Activation of complement in trauma patients has been verified by detection of elevated plasma C3a, C5a, and C5b-9 levels which correlate with disease severity [73, 300–305]. In septic patients, there is abundant evidence for complement activation and production of the anaphylatoxin C5a. In an experimental model of CLP-induced sepsis, interception of C5a or its receptors was shown to greatly improve survival in rodents, an effect that was associated with mitigation of the consumptive septic coagulopathy as well as reduction in the hyperinflammatory response, thereby reducing

intensity of MOF, and septic shock [306, 307]. However, depending on the origin or extent of the damaged macro- and micromilieu, not only activation but also inhibition of the complement system leading to a maladaptive immune response and subsequent cellular and organ dysfunctions was observed [48, 299].

Extracellular vesicles

Extracellular vesicles (EVs) comprise various small, membranous vesicles that are released from activated or dying cells. Presently, there are two distinct populations of EVs based on their size: exosomes (30–100 nm) and microparticles (100–1000 nm). Different types of EVs are generated by different mechanisms of biogenesis [308]. Exosomes form by inward budding of multivesicular bodies membranes, while microparticles and apoptotic bodies are generated by outward budding of plasma membrane [308]. This process requires cytoskeletal reformations and sequential assembly of the endosomal sorting complex on the multivesicular bodies membranes [309–311].

Upon release, EVs transfer their cargo by multiple mechanisms, such as endocytosis, phagocytosis, micropinocytosis, and membrane fusion [312, 313]. EVs carry the molecular signature of their origination cells including proteins, mRNAs, miRNAs (miRs), and lipids which make EVs effective cell-to-cell communicators [314–319]. Therefore, specific EVs from activated or dying cells can be used as biomarkers. For example, circulating EVs with liver-specific proteome markers and miRs are released from lipotoxic hepatocytes in nonalcoholic fatty liver disease [320, 321]. Recently, it was shown that damaged hepatocytes from alcoholic liver disease released a key source of EVs containing a specific microRNA “barcode” [322]. This EVs specific, i.e., microRNA “barcode” is detectable in the blood [320, 322, 323]. Next to their biomarker character, EVs are potent immune modulators. Dendritic cell-derived exosomes express major histocompatibility complex (MHC) I, MHC II, and costimulatory molecules, and they can induce antigen-specific T cell responses [324–326]. In case of cancer, it has been shown that exosomes and microparticles released from cancer cells contributed to the suppression of host immune surveillance, cancer progression and metastasis, and angiogenesis [327–329]. In various other diseases, graft-versus-host disease, chronic kidney disease, and acute radiation injury EVs have been proposed as therapeutic to modulate the inflammatory responses and tissue regeneration [330–332]. However, this remains to be considered carefully, since EVs themselves can express various procoagulants promoting the vascular thrombosis [333, 334]. Exosomes isolated from septic patients induced vascular dysfunction by inducing reactive oxygen species generation and endothelial cell apoptosis [335]. Inhibition

of the exosome release prior to endotoxin challenge or CLP in mice significantly reduced the levels of circulating exosomes and diminished sepsis-induced cardiac inflammation, myocardial dysfunction, and mortality [336, 337]. Interestingly, increasing evidence is demonstrating that the positive effects of cell-based therapies may be mediated by exosomes released from the administered cells and that the corresponding microRNA cargo in these exosomes is largely responsible for the therapeutic effects [338].

With regard to traumatic injury, recently Eguchi et al. [339] have demonstrated that liver injury in alcohol-intoxicated trauma patients with severe injury was reflected by increased systemic EV numbers, their specific miR barcode, and the correlated increase in systemic inflammatory markers IL-6 and IL-33, with IL-33 being a marker of alcoholic liver disease. Interestingly, severely injured trauma patients without liver injury were found to have a reduced number of liver-derived EVs, no observed inflammatory infiltration, and reduced specific miR “barcode” [339]. Trauma/hemorrhagic shock causes a release of proinflammatory mediators into the mesenteric lymph that may trigger a systemic inflammatory response and subsequent organ failure. Recently, it has been shown that exosomes in post-shock mesenteric lymph were biologically active mediators of this inflammation and that they carry a distinct, proinflammatory protein cargo [340, 341]. Interestingly, a stimulation of the vagus nerve prevented the T/HS-induced changes in mesenteric lymph exosome protein [341]. Subsequently, Williams et al. [341] propose a novel mechanism by which the neuroenteric axis may limit the systemic inflammatory response after injury protein. Neuroinflammation is a response against harmful effects of diverse stimuli and participates in the pathogenesis of brain and spinal cord injury. The innate immune response plays an important role in neuroinflammation following CNS injury via activation of inflammasomes [342, 343]. Interestingly, exosomes derived from neurons can deliver short-interfering RNA into the CNS to significantly decrease inflammasome activation after injury [343]. Thus, exosomes offer a new therapeutic approach to deliver RNA-based drugs to block inflammation after CNS injury. Several studies have characterized EVs in blood collected after traumatic injury, demonstrating their levels, cellular origins, adhesion molecule expression, and procoagulant activity [344–348]. Blood from patients who developed sepsis after trauma increased levels of platelet microparticles and platelet-leukocyte aggregates as compared to healthy controls were detected [344]. Kuravi et al. [349] have shown that a significant increase in plasma EVs after severe traumatic injury had procoagulant and proinflammatory effects that may influence outcomes. Thus, EVs as DAMPs may play dual roles in tissue repair and damage.

Other DAMPs

Several other DAMPs playing important roles in the initiation and regulation of immune responses as well as in the post-injury regeneration have not been addressed here. Of those, notably other mitochondria-derived DAMPs including mitochondrial formyl peptides, heme, and cytochrome (Cyt) C have not been described [46].

Heme, a tetrapyrrole containing a central iron ion, is synthesized in the mitochondria and constitutes a versatile signaling molecule controlling the activities of diverse regulators ranging from transcription factors to MAP kinases [350]. Upon severe trauma, this DAMP can bind to TLR4 and trigger a number of downstream stress response pathways, and it was suggested to play a central role in the pathogenesis of severe sepsis [351].

CytC which is also released from dying cells during cellular trauma can act as a danger signal in the extracellular space. In experiments on rabbits, oxidative injury to mitochondria has been demonstrated to be associated with high mitochondrial expression of CytC [352]. In studies on a burn model in mice, circulating CytC levels were found to be elevated eightfold within 3 h post-injury and remained elevated at 24 h [353].

Upon destruction of the red cells in the blood vessels, a significant quantity of hemoglobin and other contents of these cells are released into the circulation [354]. In case that this cell-free hemoglobin is not neutralized to its inert, non-toxic form by its scavenger proteins, significant damage in the vascular, perivascular and endothelial spaces occurs [354, 355].

Extracellular cyclophilin A (CypA) is a DAMP that has been associated with rheumatoid arthritis, liver injury and severe sepsis as well [356–358]. It can act as a chemotactic agent for inflammatory cells via the CD147 receptor, and it can directly stimulate the proinflammatory response. However, in an *in vitro* shock tube model of blast TBI with human neuroblastoma cells, a potentially neuroprotective mechanism involving released CypA has been proposed, since the accumulation of CypA in the culture medium after repeated blast exposures supported the hypothesis that extracellular CypA-mediated neuroprotection [359]. Post-exposure treatment of the cells with purified recombinant CypA confirmed this protection against blast-induced neuronal injury [359].

Uric acid can be released from injured cells as other DAMPs as well [360]. Inside the cells, it is soluble, but it precipitates to monosodium urate microcrystals in its extracellular form, exerting inflammatory properties, as evident by its accumulation in tissues and gout [49, 361]. Uric acid crystals act via inflammasomes, resulting in the production of active proinflammatory cytokines IL-1 β and IL-18 and neutrophilic influx [362]. Elevated levels of serum uric acid correlated with early acute kidney injury after severe burns

[363]. The authors propose uric acid-related aberrant inflammation to be one of the pathogenic factors [363].

Recognition, signaling and cellular response

The “danger model” was proposed as an alternative to the “self versus non-self recognition model” [364, 365]. Briefly, the immune system discriminates not only between self and non-self, but also between safe and dangerous as well, as clinically proved by Walter Land and presented by Polly Matzinger in the “Danger Model,” expanding the work of Janeway and others [70, 71, 364–367]. This complex response to stress employs numerous equivalent or comparable components of PAMPs, DAMPs, or newly introduced SAMPs, which can be found in most vertebrates, invertebrates, and even plants [23, 366–369]. These molecules are sensitized and recognized via PRR mediating very potent immune responses [370, 371]. Several classes of PRR have been identified so far, including the most prominent group of toll-like receptors (TLR), nucleotide oligomerization domain (NOD)-like receptors (NLR), members of the c-type lectin receptors (CLR) like mannose binding lectine (MBL) or receptor for advanced glycation end products (RAGE) among others [187, 370, 372, 373].

TLRs

Among TLRs, membrane-bound TLRs recognize microbial components and environmental danger signals, such as lipopolysaccharide (LPS) of gram negative, lipoteichoic acid, or peptidoglycan of Gram-positive bacteria, or even liporabinomannan of mycoplasma, and, e.g., endogenous HMGB proteins or HEME [370, 374–378]. Intracellular TLRs recognize predominantly nucleic acids derived from bacteria and viruses, such as single- or double-stranded RNA from viruses, unmethylated CpG motifs, or purine analogs and other components of cellular stress [370]. PRR signaling is intracellularly transduced, e.g., via MAPK pathways to nuclei, with subsequent activation of diverse transcription factors, including NF- κ B, and thereby induced a cellular responses [379, 380]. The cellular responses include, i.e., expression of cytokines or adhesion molecules to accelerate inflammation and diapedesis of the immune effector cells [380]. Interestingly, in a feedback loop, those inflammatory mediators themselves can induce, e.g., DAMPs to potentiate inflammation [381].

The cell surface receptor RAGE belongs to the immunoglobulin superfamily and was first described in 1992. Interestingly, RAGE is a multiligand receptor that can bind structurally diverse array of several molecules, including DAMPs like HMGB1, but also S100 family members and amyloid- β proteins [382–384]. RAGE is predominantly involved in the

recognition of endogenous molecules released in the context of infection, chronic inflammation, or physiological stress, and its activation has been confirmed in various diseases, including sepsis and cardiovascular disease among others [187, 385–387]. Since RAGE shares numerous TLR ligands, its activation can induce numerous cellular signaling pathways, which among other transcription factors modulate NF- κ B, activator protein-1, or signal transducers and activators of transcription-3 [187, 388–390]. In general, RAGE triggers a proinflammatory response, generation of nitric oxide, and several adhesion molecules but also RAGE itself causing and enhancing a continuous inflammatory response [389, 391–394].

NLR

Adjacent to TLRs, NLR sensitizes signals of cellular stress, such as ATP-induced activation of P2X7 channels and the efflux of potassium ions, host cell-free nuclear DNA, ROS as well as bacterial peptidoglycans, crystalline material, peptide aggregates, bacterial toxins and numerous others [395–397]. As part of the multiprotein inflammasome complexes, they mediate the processing of biologically inactive precursors of, e.g., IL-1 β or IL-18 into their respective bioactive forms, which furthermore promote pyroptosis, a specific form of cell death [396, 398–402]. A direct link for the NLR sensor molecule-mediated inflammasome activation via binding of either a PAMP or a DAMP is still under discussion [397, 402]. The proposed classical mechanism implies two signals, the first one mediated by a TLR [403, 404], and in parallel, the potential DAMP signal for inflammasome induction by, e.g., potassium influx or binding of ATP to P2X7 [126, 402–407]. Apart from activating certain cytokines, the inflammasome complex induces cell lysis in form of pyroptosis, which has been introduced in 2001 [408]. Pyroptosis describes the well-orchestrated lysis of the cell, which is initiated by an inflammasome activation and consecutive formation of caspase-1-dependent pores of 1–2 nm width [408]. As a consequence, cells are prone to swelling and lysis, but also to the release of intracellular molecules, which act as DAMPs, e.g., HMGB1 or ATP, which are described above. Briefly, pyroptosis is an important mode of cell death in DAMP-mediated enhancing and spreading of the inflammatory response, which mainly affects the cells of the myeloid lineage but also occurs in epithelial, endothelial cells and neurons.

CLR

CLR has been mainly described in the context of binding to PAMPs [409]. There are two groups of transmembrane CLR, like dectin-1 or dectin-2 subgroups, and a group of soluble CLR including MBL, which comprise this large family of

receptors that are expressed on most cell types including macrophages and dendritic cells [409, 410]. The signaling pathways are either mediated directly via, e.g., NF- κ B, or modulated signaling by TLR, triggering cellular phagocytosis, maturation of dendritic cells, chemotaxis, respiratory burst, and cytokine production [410]. More than 10 years ago, Yamasaki et al. [411] found that macrophage-inducible c-type lectin (Mincle) senses nonhomeostatic necrotic dead of cells due to a component of small nuclear ribonucleoprotein, spliceosome-associated protein 130 (SAP130), and induces thereby the production of inflammatory cytokines and chemokines to potentiate the neutrophilic infiltration of damaged tissue. The endogenous Mincle ligand SAP130 was confirmed as a danger signal, which can be released by damaged cells, thereby activating inflammatory responses including inflammasome activation [412].

Conclusions

This review discusses only a few of the currently discussed DAMPs that play important roles in the inflammatory or regenerative responses upon trauma. Although the provided list is certainly both incomplete and provides only a limited overview to the concept of trauma-induced DAMPs, it remains evident that due to the bivalent character and often pleiotropic effects of a DAMP, its functions in the posttraumatic inflammation and regeneration still remain to be studied in detail. However, the new insights into the contribution of DAMPs to the sepsis-like inflammation and immune paralysis-like states that can be observed in severely injured patients will be helpful in further specifying the clinical picture presented by, e.g., polytrauma. Considering the “SIRS and CARS paradigm,” and the terms mixed antagonist response syndrome and persistent inflammation, immunosuppression and catabolism syndrome, the role of these injury-induced activating and suppressing molecules clearly marks their predominant role in posttraumatic pathologies. It is indisputable that both systemic as well local presence of DAMPs is obligatory for the immune response upon traumatic insult. Yet, adjacent to their ability to be used as biomarkers to indicate or monitor disease or injury severity, and for eventual improving the timing of secondary surgery, they remain either negative or positive contributing factors for the disease development. In polytrauma, there is tentative evidence of a model suggesting that, simultaneously or somewhat retardedly with uncontrolled overshooting emission of proinflammatory DAMPs in excess (resulting in hyperinflammatory SIRS and MOF), uncontrolled overshooting generation/emission of SAMPs in excess takes place. Those “suppressing molecules” may lead to an exaggerated and long-lasting CARS associated with a stage of immunosuppression—still aimed at maintaining tissue

homeostasis. Considering this scenario, it certainly remains to be further discussed if the biologically natural attempt of the innate immune defense system to reach homeostasis via emission of SAMPs in case of severe injury-induced SIRS potentially and tragically ends up with the creation of an overshooting anti-inflammatory/proresolving and immunosuppressive milieu rendering the patient susceptible to secondary life-threatening, often lethal infections. Although the data from SAMPs involved in polytrauma are sparse and, though, the various suppressing molecules are not systematically investigated, there is preliminary evidence suggesting a role of this class of suppressing DAMPs in posttraumatic inflammation. Therefore, increased knowledge exploring the dual role of DAMPs and the interplay with SAMPs after trauma, and with their nuclear functions, transcriptional targets, release mechanisms, cellular sources, and other functions and interactions in traumatized patients is warranted. Adjacent to *in vivo* and *in vitro* studies, and furthermore, based on some contradictory findings, which often simply originate from differences between the immune system of animals and human, further clinical research is necessary to resolve this puzzle.

Funding No funding was obtained for this work.

Compliance with ethical standards

Conflict of interest The authors declare no conflicts of interest.

Informed consent No informed consent is necessary.

Human and animal rights This study does not include any human participants and/or animals.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Peden M, Hyder A. Road traffic injuries are a global public health problem. *BMJ*. 2002;324(7346):1153.
2. The global burden of disease 2013.
3. Wutzler S, et al. Pathophysiology of multiple trauma: intensive care medicine and timing of treatment. *Chirurg*. 2013;84(9):753–8.
4. Wafaisade A, et al. Epidemiology and risk factors of sepsis after multiple trauma: an analysis of 29,829 patients from the Trauma Registry of the German Society for Trauma Surgery. *Crit Care Med*. 2011;39(4):621–8.
5. Osuka A, Ogura H, Ueyama M, Shimazu T, Lederer JA. Immune response to traumatic injury: harmony and discordance of immune system homeostasis. *Acute Med Surg*. 2014;1(2):6.

6. Rose S, Marzi I. Mediators in polytrauma—pathophysiological significance and clinical relevance. *Langenbecks Arch Surg.* 1998;383(3–4):199–208.
7. Charters E, Gillett L, Simpson GK. Efficacy of electronic portable assistive devices for people with acquired brain injury: a systematic review. *Neuropsychol Rehabil.* 2015;25(1):82–121.
8. Bridgeland HJ, et al. Polytrauma in veterans: what does it mean for the medical-surgical nurse? *Medsurg Nurs.* 2014;23(4):213–7.
9. Gironda RJ, et al. Traumatic brain injury, polytrauma, and pain: challenges and treatment strategies for the polytrauma rehabilitation. *Rehabil Psychol.* 2009;54(3):247–58.
10. Bouillon B, Marzi I. The updated German “Polytrauma - Guideline”: an extensive literature evaluation and treatment recommendation for the care of the critically injured patient. *Eur J Trauma Emerg Surg.* 2018;44(Suppl 1):1.
11. Maier B, et al. Early versus late onset of multiple organ failure is associated with differing patterns of plasma cytokine biomarker expression and outcome after severe trauma. *Shock.* 2007;28(6):668–74.
12. Huber-Lang M, Lambris JD, Ward PA. Innate immune responses to trauma. *Nat Immunol.* 2018;19(4):327–41.
13. Relja B, Mors K, Marzi I. Danger signals in trauma. *Eur J Trauma Emerg Surg.* 2018;44:301–16.
14. Lord JM, et al. The systemic immune response to trauma: an overview of pathophysiology and treatment. *Lancet.* 2014;384(9952):1455–65.
15. Land WG. Allograft injury mediated by reactive oxygen species: from conserved proteins of *Drosophila* to acute and chronic rejection of human transplants. Part III: interaction of (oxidative) stress-induced heat shock proteins with toll-like receptor-bearing cells of innate immunity and its consequences for the development of acute and chronic allograft rejection. *Transplant Rev.* 2003;17(2):20.
16. Timmermans K, et al. Danger in the intensive care unit: damps in critically ill patients. *Shock.* 2016;45(2):108–16.
17. Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. *Lancet Infect Dis.* 2013;13(3):260–8.
18. Osuchowski MF, et al. Circulating cytokine/inhibitor profiles reshape the understanding of the SIRS/CARS continuum in sepsis and predict mortality. *J Immunol.* 2006;177(3):1967–74.
19. Xiao W, et al. A genomic storm in critically injured humans. *J Exp Med.* 2011;208(13):2581–90.
20. Adib-Conquy M, Cavaillon JM. Compensatory anti-inflammatory response syndrome. *Thromb Haemost.* 2009;101(1):36–47.
21. Bhan C, et al. Role of cellular events in the pathophysiology of sepsis. *Inflamm Res.* 2016;65(11):853–68.
22. Reikeras O. Immune depression in musculoskeletal trauma. *Inflamm Res.* 2010;59(6):409–14.
23. Land WG. Damage-associated molecular patterns in human diseases, vol. 1. Berlin: Springer; 2018.
24. Bone RC. Sir Isaac Newton, sepsis, SIRS, and CARS. *Crit Care Med.* 1996;24(7):1125–8.
25. Bone RC, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. *Chest.* 1992;101(6):1644–55.
26. Hoover L, et al. Systemic inflammatory response syndrome and nosocomial infection in trauma. *J Trauma.* 2006;61(2):310–6 (**discussion 316–7**).
27. Bochicchio GV, et al. Persistent systemic inflammatory response syndrome is predictive of nosocomial infection in trauma. *J Trauma.* 2002;53(2):245–50 (**discussion 250–1**).
28. Sauer A, Moore FA, Moore EE. Postinjury inflammation and organ dysfunction. *Crit Care Clin.* 2017;33(1):167–91.
29. Azevedo LC. The many facets of sepsis pathophysiology and treatment. *Shock.* 2013;39(Suppl 1):1–2.
30. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. *N Engl J Med.* 2003;348(2):138–50.
31. Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. *Nat Rev Immunol.* 2013;13(12):862–74.
32. Balk RA. Systemic inflammatory response syndrome (SIRS): where did it come from and is it still relevant today? *Virulence.* 2014;5(1):20–6.
33. Mosevoll KA, et al. Inflammatory mediator profiles differ in sepsis patients with and without bacteremia. *Front Immunol.* 2018;9:691.
34. Keel M, Trentz O. Pathophysiology of polytrauma. *Injury.* 2005;36(6):691–709.
35. Lustenberger T, et al. The severity of injury and the extent of hemorrhagic shock predict the incidence of infectious complications in trauma patients. *Eur J Trauma Emerg Surg.* 2009;35(6):538–46.
36. Tang D, et al. The molecular machinery of regulated cell death. *Cell Res.* 2019;29(5):347–64.
37. Sarabhai T, et al. Serum alpha-1 Antitrypsin (AAT) antagonizes intrinsic apoptosis induction in neutrophils from patients with systemic inflammatory response syndrome. *PLoS ONE.* 2017;12(5):e0177450.
38. Yang R, et al. HMGB1 and extracellular histones significantly contribute to systemic inflammation and multiple organ failure in acute liver failure. *Mediat Inflamm.* 2017;2017:5928078.
39. Yatim N, Cullen S, Albert ML. Dying cells actively regulate adaptive immune responses. *Nat Rev Immunol.* 2017;17(4):262–75.
40. Raymond SL, et al. Microbial recognition and danger signals in sepsis and trauma. *Biochim Biophys Acta.* 2017;1863:2564–73.
41. Tsukamoto T, Chanthaphavong RS, Pape HC. Current theories on the pathophysiology of multiple organ failure after trauma. *Injury.* 2010;41(1):21–6.
42. Horst K, et al. Impact of haemorrhagic shock intensity on the dynamic of alarmins release in porcine poly-trauma animal model. *Eur J Trauma Emerg Surg.* 2016;42(1):67–75.
43. Qiao Z, et al. Using IL-6 concentrations in the first 24 h following trauma to predict immunological complications and mortality in trauma patients: a meta-analysis. *Eur J Trauma Emerg Surg.* 2017;44:679–87.
44. Ahmed Ali M, et al. Interleukin-17 as a predictor of sepsis in polytrauma patients: a prospective cohort study. *Eur J Trauma Emerg Surg.* 2017;44:621–6.
45. Gentile LF, et al. Persistent inflammation and immunosuppression: a common syndrome and new horizon for surgical intensive care. *J Trauma Acute Care Surg.* 2012;72(6):1491–501.
46. Hauser CJ, Otterbein LE. Danger signals from mitochondrial DAMPS in trauma and post-injury sepsis. *Eur J Trauma Emerg Surg.* 2018;44(3):317–24.
47. Ward PA. New approaches to the study of sepsis. *EMBO Mol Med.* 2012;4(12):1234–43.
48. Karasu E, et al. Targeting complement pathways in polytrauma- and sepsis-induced multiple-organ dysfunction. *Front Immunol.* 2019;10:543.
49. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. *J Leukoc Biol.* 2007;81(1):1–5.
50. Manson J, Thiernemann C, Brohi K. Trauma alarmins as activators of damage-induced inflammation. *Br J Surg.* 2012;99(Suppl 1):12–20.
51. Zedler S, Faist E. The impact of endogenous triggers on trauma-associated inflammation. *Curr Opin Crit Care.* 2006;12(6):595–601.

52. Hosac AM. Drotrecogin alfa (activated): the first FDA-approved treatment for severe sepsis. *Proc (Bayl Univ Med Cent)*. 2002;15(2):224–7.
53. Kumar V. Immunometabolism: another road to sepsis and its therapeutic targeting. *Inflammation*. 2018;42(3):765–88.
54. Claessens YE, Dhainaut JF. Diagnosis and treatment of severe sepsis. *Crit Care*. 2007;11(Suppl 5):S2.
55. Russell JA. Management of sepsis. *N Engl J Med*. 2006;355(16):1699–713.
56. Giuliani A, Pirri G, Rinaldi AC. Antimicrobial peptides: the LPS connection. *Methods Mol Biol*. 2010;618:137–54.
57. Aeshnounge K, Roquilly A, Abraham E. Innate immune dysfunction in trauma patients: from pathophysiology to treatment. *Anesthesiology*. 2012;117(2):411–6.
58. Roquilly A, et al. Hydrocortisone therapy for patients with multiple trauma: the randomized controlled HYPOLYTE study. *JAMA*. 2011;305(12):1201–9.
59. Ward NS, Casserly B, Ayala A. The compensatory anti-inflammatory response syndrome (CARS) in critically ill patients. *Clin Chest Med*. 2008;29(4):617–25.
60. Islam MN, Bradley BA, Ceredig R. Sterile post-traumatic immunosuppression. *Clin Transl Immunol*. 2016;5(4):e77.
61. Bandyopadhyay G, et al. Negative signaling contributes to T-cell anergy in trauma patients. *Crit Care Med*. 2007;35(3):794–801.
62. Hensler T, et al. Distinct mechanisms of immunosuppression as a consequence of major surgery. *Infect Immun*. 1997;65(6):2283–91.
63. Hamers L, Kox M, Pickkers P. Sepsis-induced immunoparalysis: mechanisms, markers, and treatment options. *Minerva Anesthesiol*. 2015;81(4):426–39.
64. Serve R, et al. Comparative analysis of the regulatory T cells dynamics in peripheral blood in Human and porcine polytrauma. *Front Immunol*. 2018;9:435.
65. Orr SK, et al. Gene expression of proresolving lipid mediator pathways is associated with clinical outcomes in trauma patients. *Crit Care Med*. 2015;43(12):2642–50.
66. Nicolette R, et al. Prostaglandin E(2)-loaded microspheres as strategy to inhibit phagocytosis and modulate inflammatory mediators release. *Eur J Pharm Biopharm*. 2008;70(3):784–90.
67. Nemeth K, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. *Nat Med*. 2009;15(1):42–9.
68. Tsai WH, et al. Serial changes in plasma annexin A1 and cortisol levels in sepsis patients. *Chin J Physiol*. 2014;57(1):1–7.
69. Oppenheim JJ, Yang D. Alarmins: chemotactic activators of immune responses. *Curr Opin Immunol*. 2005;17(4):359–65.
70. Janeway CA Jr, Medzhitov R. Innate immune recognition. *Annu Rev Immunol*. 2002;20:197–216.
71. Matzinger P. The danger model: a renewed sense of self. *Science*. 2002;296(5566):301–5.
72. Lotze MT, et al. The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. *Immunol Rev*. 2007;220:60–81.
73. Burk AM, et al. Early complementopathy after multiple injuries in humans. *Shock*. 2012;37(4):348–54.
74. Bortolotti P, Faure E, Kipnis E. Inflammasomes in tissue damages and immune disorders after trauma. *Front Immunol*. 2018;9:1900.
75. Guisasola MC, et al. Early inflammatory response in polytraumatized patients: cytokines and heat shock proteins. A pilot study. *Orthop Traumatol Surg Res*. 2015;101(5):607–11.
76. Liaw PC, et al. DAMP and DIC: the role of extracellular DNA and DNA-binding proteins in the pathogenesis of DIC. *Blood Rev*. 2016;30(4):257–61.
77. Brinkmann V, et al. Neutrophil extracellular traps kill bacteria. *Science*. 2004;303(5663):1532–5.
78. Marin-Esteban V, et al. Afa/Dr diffusely adhering *Escherichia coli* strain C1845 induces neutrophil extracellular traps that kill bacteria and damage human enterocyte-like cells. *Infect Immun*. 2012;80(5):1891–9.
79. Choi JJ, Reich CF 3rd, Pisetsky DS. The role of macrophages in the in vitro generation of extracellular DNA from apoptotic and necrotic cells. *Immunology*. 2005;115(1):55–62.
80. Yousefi S, et al. Catapult-like release of mitochondrial DNA by eosinophils contributes to antibacterial defense. *Nat Med*. 2008;14(9):949–53.
81. Diehl F, et al. Circulating mutant DNA to assess tumor dynamics. *Nat Med*. 2008;14(9):985–90.
82. Moscoso M, Garcia E, Lopez R. Biofilm formation by *Streptococcus pneumoniae*: role of choline, extracellular DNA, and capsular polysaccharide in microbial accretion. *J Bacteriol*. 2006;188(22):7785–95.
83. Gogenur M, Burcharth J, Gogenur I. The role of total cell-free DNA in predicting outcomes among trauma patients in the intensive care unit: a systematic review. *Crit Care*. 2017;21(1):14.
84. Ahmed AI, Soliman RA, Samir S. Cell free DNA and procalcitonin as early markers of complications in ICU patients with multiple trauma and major surgery. *Clin Lab*. 2016;62(12):2395–404.
85. Ito T. PAMPs and DAMPs as triggers for DIC. *J Intensive Care*. 2014;2(1):67.
86. Vestweber D. How leukocytes cross the vascular endothelium. *Nat Rev Immunol*. 2015;15(11):692–704.
87. Sun S, et al. Mitochondrial DAMPs increase endothelial permeability through neutrophil dependent and independent pathways. *PLoS ONE*. 2013;8(3):e59989.
88. Eppensteiner J, et al. Immunothrombotic activity of damage-associated molecular patterns and extracellular vesicles in secondary organ failure induced by trauma and sterile insults. *Front Immunol*. 2018;9:190.
89. Ahmad A, Druzhyina N, Szabo C. Effect of 3-mercaptopyruvate sulfurtransferase deficiency on the development of multiorgan failure, inflammation, and wound healing in mice subjected to burn injury. *J Burn Care Res*. 2019;40(2):148–56.
90. Bianchi ME, Agresti A. HMG proteins: dynamic players in gene regulation and differentiation. *Curr Opin Genet Dev*. 2005;15(5):496–506.
91. Pandolfi F, et al. Key role of DAMP in inflammation, cancer, and tissue repair. *Clin Ther*. 2016;38(5):1017–28.
92. Belgrano FS, et al. Role of the acidic tail of high mobility group protein B1 (HMGB1) in protein stability and DNA bending. *PLoS ONE*. 2013;8(11):e79572.
93. Venereau E, Ceriotti C, Bianchi ME. DAMPs from cell death to new life. *Front Immunol*. 2015;6:422.
94. Bellussi LM, et al. Are HMGB1 protein expression and secretion markers of upper airways inflammatory diseases? *J Biol Regul Homeost Agents*. 2013;27(3):791–804.
95. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. *Nature*. 2002;418(6894):191–5.
96. Andersson U, Yang H, Harris H. High-mobility group box 1 protein (HMGB1) operates as an alarmin outside as well as inside cells. *Semin Immunol*. 2018;38:40–8.
97. Yang H, et al. A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. *Proc Natl Acad Sci U S A*. 2010;107(26):11942–7.
98. Yu L, Wang L, Chen S. Endogenous toll-like receptor ligands and their biological significance. *J Cell Mol Med*. 2010;14(11):2592–603.
99. Lu B, et al. Novel role of PKR in inflammasome activation and HMGB1 release. *Nature*. 2012;488(7413):670–4.

100. Yang H, et al. Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1). *Mol Med*. 2012;18:250–9.
101. Venereau E, et al. Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. *J Exp Med*. 2012;209(9):1519–28.
102. Schulman IG, et al. Macronuclei and micronuclei in *Tetrahymena thermophila* contain high-mobility-group-like chromosomal proteins containing a highly conserved eleven-amino-acid putative DNA-binding sequence. *Mol Cell Biol*. 1991;11(1):166–74.
103. Deng M, et al. Location is the key to function: HMGB1 in sepsis and trauma-induced inflammation. *J Leukoc Biol*. 2019;106(1):161–9.
104. Cohen MJ, et al. Early release of high mobility group box nuclear protein 1 after severe trauma in humans: role of injury severity and tissue hypoperfusion. *Crit Care*. 2009;13(6):R174.
105. Deng M, et al. The endotoxin delivery protein HMGB1 mediates caspase-11-dependent lethality in sepsis. *Immunity*. 2018;49(4):740–53.
106. Levy RM, et al. Systemic inflammation and remote organ injury following trauma require HMGB1. *Am J Physiol Regul Integr Comp Physiol*. 2007;293(4):R1538–44.
107. Zhang BF, et al. Anti-high mobility group box-1 (HMGB1) antibody attenuates kidney damage following experimental crush injury and the possible role of the tumor necrosis factor-alpha and c-Jun N-terminal kinase pathway. *J Orthop Surg Res*. 2017;12(1):110.
108. Parker TM, et al. The danger zone: systematic review of the role of HMGB1 danger signalling in traumatic brain injury. *Brain Inj*. 2017;31(1):2–8.
109. Tian X, et al. HMGB1 promotes neurovascular remodeling via RAGE in the late phase of subarachnoid hemorrhage. *Brain Res*. 2017;1670:135–45.
110. Wang KC, et al. Cerebrospinal fluid high mobility group box 1 is associated with neuronal death in subarachnoid hemorrhage. *J Cereb Blood Flow Metab*. 2017;37(2):435–43.
111. Kim JY, et al. HMGB1 contributes to the development of acute lung injury after hemorrhage. *Am J Physiol Lung Cell Mol Physiol*. 2005;288(5):L958–65.
112. Ogawa EN, et al. Contribution of high-mobility group box-1 to the development of ventilator-induced lung injury. *Am J Respir Crit Care Med*. 2006;174(4):400–7.
113. Tsung A, et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. *J Exp Med*. 2005;201(7):1135–43.
114. van Zoelen MA, et al. Pulmonary levels of high-mobility group box 1 during mechanical ventilation and ventilator-associated pneumonia. *Shock*. 2008;29(4):441–5.
115. Ueno H, et al. Contributions of high mobility group box protein in experimental and clinical acute lung injury. *Am J Respir Crit Care Med*. 2004;170(12):1310–6.
116. Abraham E, et al. HMG-1 as a mediator of acute lung inflammation. *J Immunol*. 2000;165(6):2950–4.
117. Pellegrini L, et al. HMGB1 and repair: focus on the heart. *Pharmacol Ther*. 2019;196:160–82.
118. Vogel S, et al. Platelet-derived HMGB1 is a critical mediator of thrombosis. *J Clin Invest*. 2015;125(12):4638–54.
119. Ahrens I, et al. HMGB1 binds to activated platelets via the receptor for advanced glycation end products and is present in platelet rich human coronary artery thrombi. *Thromb Haemost*. 2015;114(5):994–1003.
120. Arshad MI, Piquet-Pellorce C, Samson M. IL-33 and HMGB1 alarmins: sensors of cellular death and their involvement in liver pathology. *Liver Int*. 2012;32(8):1200–10.
121. Yang H, Tracey KJ. Targeting HMGB1 in inflammation. *Biochim Biophys Acta*. 2010;1799(1–2):149–56.
122. Tang D, et al. High-mobility group box 1, oxidative stress, and disease. *Antioxid Redox Signal*. 2011;14(7):1315–35.
123. Keyel PA. How is inflammation initiated? Individual influences of IL-1, IL-18 and HMGB1. *Cytokine*. 2014;69(1):136–45.
124. van Griensven M. Cytokines as biomarkers in polytraumatized patients. *Unfallchirurg*. 2014;117(8):699–702.
125. Dinarello CA, Goldin NP, Wolff SM. Demonstration and characterization of two distinct human leukocytic pyrogens. *J Exp Med*. 1974;139(6):1369–81.
126. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. *Blood*. 2011;117(14):3720–32.
127. Dinarello CA. A clinical perspective of IL-1beta as the gatekeeper of inflammation. *Eur J Immunol*. 2011;41(5):1203–17.
128. Aden N, et al. Epithelial cells promote fibroblast activation via IL-1alpha in systemic sclerosis. *J Invest Dermatol*. 2010;130(9):2191–200.
129. Rosenwasser LJ, Dinarello CA, Rosenthal AS. Adherent cell function in murine T-lymphocyte antigen recognition. IV. Enhancement of murine T-cell antigen recognition by human leukocytic pyrogen. *J Exp Med*. 1979;150(3):709–14.
130. Bertheloot D, Latz E. HMGB1, IL-1alpha, IL-33 and S100 proteins: dual-function alarmins. *Cell Mol Immunol*. 2017;14(1):43–64.
131. Kobayashi Y, et al. Identification of calcium-activated neutral protease as a processing enzyme of human interleukin 1 alpha. *Proc Natl Acad Sci U S A*. 1990;87(14):5548–52.
132. Kavita U, Mizel SB. Differential sensitivity of interleukin-1 alpha and -beta precursor proteins to cleavage by calpain, a calcium-dependent protease. *J Biol Chem*. 1995;270(46):27758–65.
133. Carruth LM, Demczuk S, Mizel SB. Involvement of a calpain-like protease in the processing of the murine interleukin 1 alpha precursor. *J Biol Chem*. 1991;266(19):12162–7.
134. Weber A, Wasiliew P, Kracht M. Interleukin-1 (IL-1) pathway. *Sci Signal*. 2010;3(105):cm1.
135. Lefrancais E, Cayrol C. Mechanisms of IL-33 processing and secretion: differences and similarities between IL-1 family members. *Eur Cytokine Netw*. 2012;23(4):120–7.
136. Maier JA, Statuto M, Ragnotti G. Endogenous interleukin 1 alpha must be transported to the nucleus to exert its activity in human endothelial cells. *Mol Cell Biol*. 1994;14(3):1845–51.
137. Werman A, et al. The precursor form of IL-1alpha is an intracrine proinflammatory activator of transcription. *Proc Natl Acad Sci U S A*. 2004;101(8):2434–9.
138. Sakurai T, et al. Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. *Cancer Cell*. 2008;14(2):156–65.
139. Carta S, Lavieri R, Rubartelli A. Different members of the IL-1 family come out in different ways: DAMPs vs. cytokines? *Front Immunol*. 2013;4:123.
140. Ballak DB, et al. IL-1 family members in the pathogenesis and treatment of metabolic disease: focus on adipose tissue inflammation and insulin resistance. *Cytokine*. 2015;75(2):280–90.
141. Di Paolo NC, Shayakhmetov DM. Interleukin 1alpha and the inflammatory process. *Nat Immunol*. 2016;17(8):906–13.
142. Lugin J, et al. Cutting edge: IL-1alpha is a crucial danger signal triggering acute myocardial inflammation during myocardial infarction. *J Immunol*. 2015;194(2):499–503.
143. Scarpa M, et al. The epithelial danger signal IL-1alpha is a potent activator of fibroblasts and reactivator of intestinal inflammation. *Am J Pathol*. 2015;185(6):1624–37.
144. Jackman RP, et al. Distinct roles of trauma and transfusion in induction of immune modulation after injury. *Transfusion*. 2012;52(12):2533–50.

145. Ehrnthaller C, et al. The molecular fingerprint of lung inflammation after blunt chest trauma. *Eur J Med Res.* 2015;20:70.
146. Jacobs RF, et al. Elevated interleukin-1 release by human alveolar macrophages during the adult respiratory distress syndrome. *Am Rev Respir Dis.* 1989;140(6):1686–92.
147. Rider P, et al. The transcription of the alarmin cytokine interleukin-1 alpha is controlled by hypoxia inducible factors 1 and 2 alpha in hypoxic cells. *Front Immunol.* 2012;3:290.
148. Thornton P, et al. Platelet interleukin-1alpha drives cerebrovascular inflammation. *Blood.* 2010;115(17):3632–9.
149. Turner NA, et al. Interleukin-1alpha stimulates proinflammatory cytokine expression in human cardiac myofibroblasts. *Am J Physiol Heart Circ Physiol.* 2009;297(3):H1117–27.
150. Pichery M, et al. Endogenous IL-33 is highly expressed in mouse epithelial barrier tissues, lymphoid organs, brain, embryos, and inflamed tissues: in situ analysis using a novel IL-33-LacZ gene trap reporter strain. *J Immunol (Baltimore, Md.: 1950).* 2012;188(7):3488–95.
151. Baekkevold ES, et al. Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules. *Am J Pathol.* 2003;163(1):69–79.
152. Liew FY, Girard JP, Turnquist HR. Interleukin-33 in health and disease. *Nat Rev Immunol.* 2016;16(11):676–89.
153. Carriere V, et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. *Proc Natl Acad Sci USA.* 2007;104(1):282–7.
154. Hirsiger S, et al. Danger signals activating the immune response after trauma. *Mediat Inflamm.* 2012;2012:315941.
155. Schmitz J, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. *Immunity.* 2005;23(5):479–90.
156. Palmer G, et al. The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33. *Cytokine.* 2008;42(3):358–64.
157. Arpaia N, et al. A distinct function of regulatory T cells in tissue protection. *Cell.* 2015;162(5):1078–89.
158. Molofsky AB, Savage AK, Locksley RM. Interleukin-33 in tissue homeostasis, injury, and inflammation. *Immunity.* 2015;42(6):1005–19.
159. Lefrancais E, et al. IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G. *Proc Natl Acad Sci U S A.* 2012;109(5):1673–8.
160. Roussel L, et al. Molecular mimicry between IL-33 and KSHV for attachment to chromatin through the H2A-H2B acidic pocket. *EMBO Rep.* 2008;9(10):1006–12.
161. Bessa J, et al. Altered subcellular localization of IL-33 leads to non-resolving lethal inflammation. *J Autoimmun.* 2014;55:33–41.
162. Cohen ES, et al. Oxidation of the alarmin IL-33 regulates ST2-dependent inflammation. *Nat Commun.* 2015;6:8327.
163. Cayrol C, Girard J-P. IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy. *Curr Opin Immunol.* 2014;31:31–7.
164. Ali S, et al. IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells. *Proc Natl Acad Sci U S A.* 2007;104(47):18660–5.
165. Kurowska-Stolarska M, et al. IL-33 induces antigen-specific IL-5+ T cells and promotes allergic-induced airway inflammation independent of IL-4. *J Immunol.* 2008;181(7):4780–90.
166. Jovanovic IP, et al. IL-33/ST2 axis in innate and acquired immunity to tumors. *Oncoimmunology.* 2012;1(2):229–31.
167. Liu Q, et al. IL-33-mediated IL-13 secretion by ST2+ Tregs controls inflammation after lung injury. *JCI Insight.* 2019. <https://doi.org/10.1172/jci.insight.123919>.
168. Humphreys NE, et al. IL-33, a potent inducer of adaptive immunity to intestinal nematodes. *J Immunol.* 2008;180(4):2443–9.
169. Alves-Filho JC, et al. Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection. *Nat Med.* 2010;16(6):708–12.
170. Kurowska-Stolarska M, et al. IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. *J Immunol.* 2009;183(10):6469–77.
171. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. *N Engl J Med.* 2008;359(22):2355–65.
172. Palmer G, et al. Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. *Arthritis Rheum.* 2009;60(3):738–49.
173. Gadani SP, et al. The glia-derived alarmin IL-33 orchestrates the immune response and promotes recovery following CNS injury. *Neuron.* 2015;85(4):703–9.
174. Wicher G, et al. Interleukin-33 promotes recruitment of microglia/macrophages in response to traumatic brain injury. *J Neurotrauma.* 2017;34(22):3173–82.
175. Pomeschik Y, et al. Interleukin-33 treatment reduces secondary injury and improves functional recovery after contusion spinal cord injury. *Brain Behav Immun.* 2015;44:68–81.
176. Foster SL, Talbot S, Woolf CJ. CNS injury: IL-33 sounds the alarm. *Immunity.* 2015;42(3):403–5.
177. Foell D, et al. S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. *J Leukoc Biol.* 2007;81(1):28–37.
178. Foell D, et al. Expression of S100A12 (EN-RAGE) in cystic fibrosis. *Thorax.* 2003;58(7):613–7.
179. Oesterle A, Bowman MA. S100A12 and the S100/calgranulins: emerging biomarkers for atherosclerosis and possibly therapeutic targets. *Arterioscler Thromb Vasc Biol.* 2015;35(12):2496–507.
180. Dassan P, Keir G, Brown MM. Criteria for a clinically informative serum biomarker in acute ischaemic stroke: a review of S100B. *Cerebrovasc Dis.* 2009;27(3):295–302.
181. Gogas H, et al. Biomarkers in melanoma. *Ann Oncol.* 2009;20(Suppl 6):vi8–13.
182. Gazzolo D, Michetti F. Perinatal S100B protein assessment in human unconventional biological fluids: a minireview and new perspectives. *Cardiovasc Psychiatry Neurol.* 2010;2010:703563.
183. Mocellin S, Zavagno G, Nitti D. The prognostic value of serum S100B in patients with cutaneous melanoma: a meta-analysis. *Int J Cancer.* 2008;123(10):2370–6.
184. Ellis EF, et al. S100B protein is released from rat neonatal neurons, astrocytes, and microglia by in vitro trauma and anti-S100 increases trauma-induced delayed neuronal injury and negates the protective effect of exogenous S100B on neurons. *J Neurochem.* 2007;101(6):1463–70.
185. Pruenster M, et al. S100A8/A9: from basic science to clinical application. *Pharmacol Ther.* 2016;167:120–31.
186. Ghavami S, et al. S100A8/A9 at low concentration promotes tumor cell growth via RAGE ligation and MAP kinase-dependent pathway. *J Leukoc Biol.* 2008;83(6):1484–92.
187. Ibrahim ZA, et al. RAGE and TLRs: relatives, friends or neighbours? *Mol Immunol.* 2013;56(4):739–44.
188. Loeser RF, et al. Articular chondrocytes express the receptor for advanced glycation end products: potential role in osteoarthritis. *Arthritis Rheum.* 2005;52(8):2376–85.
189. Rohde D, et al. S100A1 is released from ischemic cardiomyocytes and signals myocardial damage via Toll-like receptor 4. *EMBO Mol Med.* 2014;6(6):778–94.
190. Payen D, et al. Gene profiling in human blood leucocytes during recovery from septic shock. *Intensive Care Med.* 2008;34(8):1371–6.

191. Zhang LN, et al. Diagnostic and predictive levels of calcium-binding protein A8 and tumor necrosis factor receptor-associated factor 6 in sepsis-associated encephalopathy: a prospective observational study. *Chin Med J (Engl)*. 2016;129(14):1674–81.
192. Uhel F, et al. Early expansion of circulating granulocytic myeloid-derived suppressor cells predicts development of nosocomial infections in patients with sepsis. *Am J Respir Crit Care Med*. 2017;196(3):315–27.
193. Fontaine M, et al. Innate danger signals in acute injury: from bench to bedside. *Anaesth Crit Care Pain Med*. 2016;35(4):283–92.
194. De Lorenzo BH, et al. Macrophage suppression following phagocytosis of apoptotic neutrophils is mediated by the S100A9 calcium-binding protein. *Immunobiology*. 2010;215(5):341–7.
195. Azmitia EC. Cajal's hypotheses on neurobioes and neurotropic factor match properties of microtubules and S-100 beta. *Prog Brain Res*. 2002;136:87–100.
196. Van Eldik LJ, Wainwright MS. The Janus face of glial-derived S100B: beneficial and detrimental functions in the brain. *Restor Neurol Neurosci*. 2003;21(3–4):97–108.
197. Thelin EP, et al. Assessing bicycle-related trauma using the biomarker S100B reveals a correlation with total injury severity. *Eur J Trauma Emerg Surg*. 2016;42(5):617–25.
198. Adami C, et al. S100B expression in and effects on microglia. *Glia*. 2001;33(2):131–42.
199. Goyal A, et al. S100b as a prognostic biomarker in outcome prediction for patients with severe traumatic brain injury. *J Neurotrauma*. 2013;30(11):946–57.
200. Kellermann I, et al. Early CSF and serum S100B concentrations for outcome prediction in traumatic brain injury and subarachnoid hemorrhage. *Clin Neurol Neurosurg*. 2016;145:79–83.
201. Rezaei O, et al. S100 B: a new concept in neurocritical care. *Iran J Neurol*. 2017;16(2):83–9.
202. Holzinger D, Tenbrock K, Roth J. Alarmins of the S100-family in juvenile autoimmune and auto-inflammatory diseases. *Front Immunol*. 2019;10:182.
203. Golden N, et al. S100B serum level as a mortality predictor for traumatic brain injury: a meta-analysis. *Open Access Maced J Med Sci*. 2018;6(11):2239–44.
204. Chernov AV, et al. The calcium-binding proteins S100A8 and S100A9 initiate the early inflammatory program in injured peripheral nerves. *J Biol Chem*. 2015;290(18):11771–84.
205. Austermann J, et al. Alarmins MRP8 and MRP14 induce stress tolerance in phagocytes under sterile inflammatory conditions. *Cell Rep*. 2014;9(6):2112–23.
206. Dang X, et al. S100B ranks as a new marker of multiple traumas in patients and may accelerate its development by regulating endothelial cell dysfunction. *Int J Clin Exp Pathol*. 2014;7(7):3818–26.
207. Anderson RE, et al. High serum S100B levels for trauma patients without head injuries. *Neurosurgery*. 2001;48(6):1255–8 (**discussion 1258–60**).
208. Pfortmueller CA, et al. S-100 B concentrations are a predictor of decreased survival in patients with major trauma, independently of head injury. *PLoS ONE*. 2016;11(3):e0152822.
209. Greven J, et al. Update on the role of endothelial cells in trauma. *Eur J Trauma Emerg Surg*. 2017;44:667–77.
210. Wang J, et al. Injury-induced MRP8/MRP14 stimulates IP-10/CXCL10 in monocytes/macrophages. *FASEB J*. 2015;29(1):250–62.
211. Kawai C, et al. Circulating extracellular histones are clinically relevant mediators of multiple organ injury. *Am J Pathol*. 2016;186(4):829–43.
212. Silk E, et al. The role of extracellular histone in organ injury. *Cell Death Dis*. 2017;8(5):e2812.
213. Huang H, et al. Endogenous histones function as alarmins in sterile inflammatory liver injury through Toll-like receptor 9 in mice. *Hepatology*. 2011;54(3):999–1008.
214. Tang D, et al. PAMPs and DAMPs: signal 0s that spur autophagy and immunity. *Immunol Rev*. 2012;249(1):158–75.
215. Hirsch JG. Bactericidal action of histone. *J Exp Med*. 1958;108(6):925–44.
216. Pisetsky DS. Immune activation by histones: pluses and minuses in inflammation. *Eur J Immunol*. 2013;43(12):3163–6.
217. Xu J, et al. Extracellular histones are major mediators of death in sepsis. *Nat Med*. 2009;15(11):1318–21.
218. Toh CH, Alhamdi Y, Abrams ST. Current pathological and laboratory considerations in the diagnosis of disseminated intravascular coagulation. *Ann Lab Med*. 2016;36(6):505–12.
219. Alhamdi Y, et al. Circulating histones are major mediators of cardiac injury in patients with sepsis. *Crit Care Med*. 2015;43(10):2094–103.
220. Allam R, et al. Histones from dying renal cells aggravate kidney injury via TLR2 and TLR4. *J Am Soc Nephrol*. 2012;23(8):1375–88.
221. Semeraro F, et al. Extracellular histones promote thrombin generation through platelet-dependent mechanisms: involvement of platelet TLR2 and TLR4. *Blood*. 2011;118(7):1952–61.
222. Abrams ST, et al. Circulating histones are mediators of trauma-associated lung injury. *Am J Respir Crit Care Med*. 2013;187(2):160–9.
223. Kalbitz M, et al. Cardiac depression in pigs after multiple trauma—characterization of posttraumatic structural and functional alterations. *Sci Rep*. 2017;7(1):17861.
224. Guisasaola MC, et al. An overview of cytokines and heat shock response in polytraumatized patients. *Cell Stress Chaperones*. 2018;23(4):483–9.
225. De Maio A. Heat shock proteins: facts, thoughts, and dreams. *Shock*. 1999;11(1):1–12.
226. DeMeester SL, Buchman TG, Cobb JP. The heat shock paradox: does NF-kappaB determine cell fate? *FASEB J*. 2001;15(1):270–4.
227. Ritossa F. Discovery of the heat shock response. *Cell Stress Chaperones*. 1996;1(2):97–8.
228. Schopf FH, Biebl MM, Buchner J. The HSP90 chaperone machinery. *Nat Rev Mol Cell Biol*. 2017;18(6):345–60.
229. Kim JY, Yenari MA. The immune modulating properties of the heat shock proteins after brain injury. *Anat Cell Biol*. 2013;46(1):1–7.
230. Calderwood SK, et al. Extracellular heat shock proteins in cell signaling. *FEBS Lett*. 2007;581(19):3689–94.
231. Csermely P. The biology of extracellular molecular chaperones. Chair's introduction. *Novartis Found Symp*. 2008;291:1–2.
232. Arnold-Schild D, et al. Cutting edge: receptor-mediated endocytosis of heat shock proteins by professional antigen-presenting cells. *J Immunol*. 1999;162(7):3757–60.
233. Fong JJ, et al. Immunomodulatory activity of extracellular Hsp70 mediated via paired receptors Siglec-5 and Siglec-14. *EMBO J*. 2015;34(22):2775–88.
234. Tang D, et al. The anti-inflammatory effects of heat shock protein 72 involve inhibition of high-mobility-group box 1 release and proinflammatory function in macrophages. *J Immunol*. 2007;179(2):1236–44.
235. Turturici G, Sconzo G, Geraci F. Hsp70 and its molecular role in nervous system diseases. *Biochem Res Int*. 2011;2011:618127.
236. Giffard RG, Yenari MA. Many mechanisms for hsp70 protection from cerebral ischemia. *J Neurosurg Anesthesiol*. 2004;16(1):53–61.

237. Adachi H, et al. Heat shock proteins in neurodegenerative diseases: pathogenic roles and therapeutic implications. *Int J Hyperth*. 2009;25(8):647–54.
238. Wheeler DS, et al. Extracellular heat shock protein 60 (Hsp60) levels in children with septic shock. *Inflamm Res*. 2007;56(5):216–9.
239. Wheeler DS, et al. Extracellular hsp70 levels in children with septic shock. *Pediatr Crit Care Med*. 2005;6(3):308–11.
240. Hashiguchi N, et al. Enhanced expression of heat shock proteins in activated polymorphonuclear leukocytes in patients with sepsis. *J Trauma*. 2001;51(6):1104–9.
241. Chatterjee A, et al. Heat shock protein 90 inhibitors prolong survival, attenuate inflammation, and reduce lung injury in murine sepsis. *Am J Respir Crit Care Med*. 2007;176(7):667–75.
242. Singleton KD, Wischmeyer PE. Effects of HSP70.1/3 gene knockout on acute respiratory distress syndrome and the inflammatory response following sepsis. *Am J Physiol Lung Cell Mol Physiol*. 2006;290(5):L956–61.
243. McConnell KW, et al. The role of heat shock protein 70 in mediating age-dependent mortality in sepsis. *J Immunol*. 2011;186(6):3718–25.
244. Hashiguchi N, et al. Enhanced expression of heat shock proteins in leukocytes from trauma patients. *J Trauma*. 2001;50(1):102–7.
245. Ogura H, et al. Long-term enhanced expression of heat shock proteins and decelerated apoptosis in polymorphonuclear leukocytes from major burn patients. *J Burn Care Rehabil*. 2002;23(2):103–9.
246. Pespeni M, et al. Serum levels of Hsp60 correlate with the development of acute lung injury after trauma. *J Surg Res*. 2005;126(1):41–7.
247. Pockley AG, Muthana M, Calderwood SK. The dual immunoregulatory roles of stress proteins. *Trends Biochem Sci*. 2008;33(2):71–9.
248. Pittet JF, et al. Serum levels of Hsp 72 measured early after trauma correlate with survival. *J Trauma*. 2002;52(4):611–7 (**discussion 617**).
249. Ren B, et al. Serum levels of HSP70 and other DAMP proteins can aid in patient diagnosis after traumatic injury. *Cell Stress Chaperones*. 2016;21(4):677–86.
250. Dehbi M, et al. Hsp-72, a candidate prognostic indicator of heat-stroke. *Cell Stress Chaperones*. 2010;15(5):593–603.
251. Vardas K, et al. Early response roles for prolactin cortisol and circulating and cellular levels of heat shock proteins 72 and 90alpha in severe sepsis and SIRS. *Biomed Res Int*. 2014;2014:803561.
252. Hietbrink F, et al. Trauma: the role of the innate immune system. *World J Emerg Surg*. 2006;1:15.
253. Ma KC, et al. The role of danger signals in the pathogenesis and perpetuation of critical illness. *Am J Respir Crit Care Med*. 2018;197(3):300–9.
254. Lee YL, et al. Blood transfusion products contain mitochondrial DNA damage-associated molecular patterns: a potential effector of transfusion-related acute lung injury. *J Surg Res*. 2014;191(2):286–9.
255. Preissner KT, Herwald H. Extracellular nucleic acids in immunity and cardiovascular responses: between alert and disease. *Thromb Haemost*. 2017;117(7):1272–82.
256. Zhang Q, et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. *Nature*. 2010;464(7285):104–7.
257. Liew FY, et al. Negative regulation of toll-like receptor-mediated immune responses. *Nat Rev Immunol*. 2005;5(6):446–58.
258. Miyake K, et al. Mechanisms controlling nucleic acid-sensing Toll-like receptors. *Int Immunol*. 2018;30(2):43–51.
259. Roers A, Hiller B, Hornung V. Recognition of endogenous nucleic acids by the innate immune system. *Immunity*. 2016;44(4):739–54.
260. West AP, Shadel GS. Mitochondrial DNA in innate immune responses and inflammatory pathology. *Nat Rev Immunol*. 2017;17(6):363–75.
261. Barber GN. STING-dependent cytosolic DNA sensing pathways. *Trends Immunol*. 2014;35(2):88–93.
262. Thuraiajah K, Briggs GD, Balogh ZJ. The source of cell-free mitochondrial DNA in trauma and potential therapeutic strategies. *Eur J Trauma Emerg Surg*. 2018;44(3):325–34.
263. Deane JA, Bolland S. Nucleic acid-sensing TLRs as modifiers of autoimmunity. *J Immunol*. 2006;177(10):6573–8.
264. Saitoh S, Miyake K. Regulatory molecules required for nucleotide-sensing Toll-like receptors. *Immunol Rev*. 2009;227(1):32–43.
265. Barton GM, Kagan JC, Medzhitov R. Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA. *Nat Immunol*. 2006;7(1):49–56.
266. Sipes JN, et al. A prospective study of plasma DNA in the diagnosis of pulmonary embolism. *Am Rev Respir Dis*. 1978;118(3):475–8.
267. Arnalich F, et al. Plasma levels of mitochondrial and nuclear DNA in patients with massive pulmonary embolism in the emergency department: a prospective cohort study. *Crit Care*. 2013;17(3):R90.
268. Fuchs TA, et al. Extracellular DNA traps promote thrombosis. *Proc Natl Acad Sci U S A*. 2010;107(36):15880–5.
269. Kung CT, et al. Plasma nuclear and mitochondrial DNA levels as predictors of outcome in severe sepsis patients in the emergency room. *J Transl Med*. 2012;10:130.
270. Itagaki K, et al. Mitochondrial DNA released by trauma induces neutrophil extracellular traps. *PLoS ONE*. 2015;10(3):e0120549.
271. Cedervall J, Zhang Y, Olsson AK. Tumor-induced NETosis as a risk factor for metastasis and organ failure. *Cancer Res*. 2016;76(15):4311–5.
272. Lee KH, et al. Neutrophil extracellular traps (NETs) in autoimmune diseases: a comprehensive review. *Autoimmun Rev*. 2017;16(11):1160–73.
273. Sandler N, et al. Mitochondrial DAMPs are released during cardiopulmonary bypass surgery and are associated with postoperative atrial fibrillation. *Heart Lung Circ*. 2018;27(1):122–9.
274. Zou J, et al. Rapid detection of donor cell free DNA in lung transplant recipients with rejections using donor-recipient HLA mismatch. *Hum Immunol*. 2017;78(4):342–9.
275. Elmore S. Apoptosis: a review of programmed cell death. *Toxicol Pathol*. 2007;35(4):495–516.
276. Rock KL, Kono H. The inflammatory response to cell death. *Annu Rev Pathol*. 2008;3:99–126.
277. Wilkins HM, et al. Mitochondria-derived damage-associated molecular patterns in neurodegeneration. *Front Immunol*. 2017;8:508.
278. Simmons JD, et al. Elevated levels of plasma mitochondrial DNA DAMPs are linked to clinical outcome in severely injured human subjects. *Ann Surg*. 2013;258(4):591–6 (**discussion 596-8**).
279. Lam NY, et al. Plasma mitochondrial DNA concentrations after trauma. *Clin Chem*. 2004;50(1):213–6.
280. Gu X, et al. The plasma mitochondrial DNA is an independent predictor for post-traumatic systemic inflammatory response syndrome. *PLoS ONE*. 2013;8(8):e72834.
281. Lo YM, et al. Plasma DNA as a prognostic marker in trauma patients. *Clin Chem*. 2000;46(3):319–23.
282. Gan L, et al. Significance of serum mtDNA concentration in lung injury induced by hip fracture. *Shock*. 2015;44(1):52–7.
283. Zhang Q, Itagaki K, Hauser CJ. Mitochondrial DNA is released by shock and activates neutrophils via p38 map kinase. *Shock*. 2010;34(1):55–9.

284. McIlroy DJ, et al. Cell necrosis-independent sustained mitochondrial and nuclear DNA release following trauma surgery. *J Trauma Acute Care Surg.* 2015;78(2):282–8.
285. Hauser CJ, et al. Mitochondrial damage associated molecular patterns from femoral reamings activate neutrophils through formyl peptide receptors and P44/42 MAP kinase. *J Orthop Trauma.* 2010;24(9):534–8.
286. Puyo CA, et al. Endotracheal tube-induced sore throat pain and inflammation is coupled to the release of mitochondrial DNA. *Mol Pain.* 2017;13:1744806917731696.
287. Yousefi S, et al. Viable neutrophils release mitochondrial DNA to form neutrophil extracellular traps. *Cell Death Differ.* 2009;16(11):1438–44.
288. Prikhodko AS, et al. Pure mitochondrial DNA does not activate human neutrophils in vitro. *Biochemistry (Mosc).* 2015;80(5):629–35.
289. Willart MA, Lambrecht BN. The danger within: endogenous danger signals, atopy and asthma. *Clin Exp Allergy.* 2009;39(1):12–9.
290. Novak I. ATP as a signaling molecule: the exocrine focus. *News Physiol Sci.* 2003;18:12–7.
291. Martinon F. Detection of immune danger signals by NALP3. *J Leukoc Biol.* 2008;83(3):507–11.
292. Elliott MR, et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. *Nature.* 2009;461(7261):282–6.
293. Chen Y, et al. ATP release guides neutrophil chemotaxis via P2Y2 and A3 receptors. *Science.* 2006;314(5806):1792–5.
294. Junger WG. Immune cell regulation by autocrine purinergic signalling. *Nat Rev Immunol.* 2011;11(3):201–12.
295. Giuliani AL, et al. The P2X7 receptor-interleukin-1 liaison. *Front Pharmacol.* 2017;8:123.
296. Peiseler M, Kubes P. More friend than foe: the emerging role of neutrophils in tissue repair. *J Clin Invest.* 2019;129(7):2629–39.
297. Li X, et al. Systemic adenosine triphosphate impairs neutrophil chemotaxis and host defense in sepsis. *Crit Care Med.* 2017;45(1):e97–104.
298. Hasan D, Blankman P, Nieman GF. Purinergic signalling links mechanical breath profile and alveolar mechanics with the pro-inflammatory innate immune response causing ventilation-induced lung injury. *Purinergic Signal.* 2017;13(3):363–86.
299. Chakraborty S, Karasu E, Huber-Lang M. Complement after trauma: suturing innate and adaptive immunity. *Front Immunol.* 2018;9:2050.
300. Frohlich M, et al. Epidemiology and risk factors of multiple-organ failure after multiple trauma: an analysis of 31,154 patients from the TraumaRegister DGU. *J Trauma Acute Care Surg.* 2014;76(4):921–7 (**discussion 927–8**).
301. Hecke F, et al. Circulating complement proteins in multiple trauma patients—correlation with injury severity, development of sepsis, and outcome. *Crit Care Med.* 1997;25(12):2015–24.
302. Ganter MT, et al. Role of the alternative pathway in the early complement activation following major trauma. *Shock.* 2007;28(1):29–34.
303. Rittirsch D, Redl H, Huber-Lang M. Role of complement in multi-organ failure. *Clin Dev Immunol.* 2012;2012:962927.
304. Paredes RM, et al. Generation of complement molecular complex C5b-9 (C5b-9) in response to poly-traumatic hemorrhagic shock and evaluation of C5 cleavage inhibitors in non-human primates. *Int Immunopharmacol.* 2018;54:221–5.
305. Li Y, et al. Complement inhibition ameliorates blast-induced acute lung injury in rats: potential role of complement in intracellular HMGB1-mediated inflammation. *PLoS ONE.* 2018;13(8):e0202594.
306. Ward PA. The harmful role of c5a on innate immunity in sepsis. *J Innate Immun.* 2010;2(5):439–45.
307. Yan C, Gao H. New insights for C5a and C5a receptors in sepsis. *Front Immunol.* 2012;3:368.
308. Colombo M, Raposo G, Thery C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. *Annu Rev Cell Dev Biol.* 2014;30:255–89.
309. Muralidharan-Chari V, et al. ARF6-regulated shedding of tumor cell-derived plasma membrane microvesicles. *Curr Biol.* 2009;19(22):1875–85.
310. Lima LG, et al. Tumor-derived microvesicles modulate the establishment of metastatic melanoma in a phosphatidylserine-dependent manner. *Cancer Lett.* 2009;283(2):168–75.
311. Iraci N, et al. Focus on extracellular vesicles: physiological role and signalling properties of extracellular membrane vesicles. *Int J Mol Sci.* 2016;17(2):171.
312. Mulcahy LA, Pink RC, Carter DR. Routes and mechanisms of extracellular vesicle uptake. *J Extracell Vesicles.* 2014;3:24641.
313. Montecalvo A, et al. Mechanism of transfer of functional microRNAs between mouse dendritic cells via exosomes. *Blood.* 2012;119(3):756–66.
314. Morel O, et al. Microparticles: a critical component in the nexus between inflammation, immunity, and thrombosis. *Semin Immunopathol.* 2011;33(5):469–86.
315. Rautou PE, et al. Microparticles, vascular function, and atherothrombosis. *Circ Res.* 2011;109(5):593–606.
316. Diehl P, et al. Microparticles: major transport vehicles for distinct microRNAs in circulation. *Cardiovasc Res.* 2012;93(4):633–44.
317. Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. *J Cell Biol.* 2013;200(4):373–83.
318. Eguchi A, et al. Microparticles release by adipocytes act as “find-me” signals to promote macrophage migration. *PLoS ONE.* 2015;10(4):e0123110.
319. Yanez-Mo M, et al. Biological properties of extracellular vesicles and their physiological functions. *J Extracell Vesicles.* 2015;4:27066.
320. Povero D, et al. Lipid-induced toxicity stimulates hepatocytes to release angiogenic microparticles that require Vanin-1 for uptake by endothelial cells. *Sci Signal.* 2013;6(296):ra88.
321. Povero D, et al. Circulating extracellular vesicles with specific proteome and liver microRNAs are potential biomarkers for liver injury in experimental fatty liver disease. *PLoS ONE.* 2014;9(12):e113651.
322. Eguchi A, et al. Extracellular vesicles released by hepatocytes from gastric infusion model of alcoholic liver disease contain a MicroRNA barcode that can be detected in blood. *Hepatology.* 2017;65(2):475–90.
323. Momen-Heravi F, et al. Exosomes derived from alcohol-treated hepatocytes horizontally transfer liver specific miRNA-122 and sensitize monocytes to LPS. *Sci Rep.* 2015;5:9991.
324. Zitvogel L, et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. *Nat Med.* 1998;4(5):594–600.
325. Liu Q, et al. Donor dendritic cell-derived exosomes promote allograft-targeting immune response. *J Clin Invest.* 2016;126(8):2805–20.
326. Marino J, et al. Donor exosomes rather than passenger leukocytes initiate alloreactive T cell responses after transplantation. *Sci Immunol.* 2016;1(1):aaf8759.
327. Zhang HG, Grizzle WE. Exosomes and cancer: a newly described pathway of immune suppression. *Clin Cancer Res.* 2011;17(5):959–64.
328. Rak J. Microparticles in cancer. *Semin Thromb Hemost.* 2010;36(8):888–906.
329. Hood JL, San RS, Wickline SA. Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. *Cancer Res.* 2011;71(11):3792–801.

330. Chang PY, et al. The potential of mesenchymal stem cells in the management of radiation enteropathy. *Cell Death Dis.* 2015;6:e1840.
331. Kordelas L, et al. MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease. *Leukemia.* 2014;28(4):970–3.
332. Nassar W, et al. Umbilical cord mesenchymal stem cells derived extracellular vesicles can safely ameliorate the progression of chronic kidney diseases. *Biomater Res.* 2016;20:21.
333. Gardiner C, et al. Extracellular vesicles, tissue factor, cancer and thrombosis—discussion themes of the ISEV 2014 Educational Day. *J Extracell Vesicles.* 2015;4:26901.
334. Muhsin-Sharafaldine MR, et al. Procoagulant and immunogenic properties of melanoma exosomes, microvesicles and apoptotic vesicles. *Oncotarget.* 2016;7(35):56279–94.
335. Janiszewski M, et al. Platelet-derived exosomes of septic individuals possess proapoptotic NAD(P)H oxidase activity: a novel vascular redox pathway. *Crit Care Med.* 2004;32(3):818–25.
336. Essandoh K, et al. Blockade of exosome generation with GW4869 dampens the sepsis-induced inflammation and cardiac dysfunction. *Biochim Biophys Acta.* 2015;1852(11):2362–71.
337. Trajkovic K, et al. Ceramide triggers budding of exosome vesicles into multivesicular endosomes. *Science.* 2008;319(5867):1244–7.
338. Zhang ZG, Buller B, Chopp M. Exosomes—beyond stem cells for restorative therapy in stroke and neurological injury. *Nat Rev Neurol.* 2019;15(4):193–203.
339. Eguchi A, et al. Circulating extracellular vesicles and their miR “Barcode” differentiate alcohol drinkers with liver injury and those without liver injury in severe trauma patients. *Front Med (Lausanne).* 2019;6:30.
340. Kojima M, et al. Exosomes, not protein or lipids, in mesenteric lymph activate inflammation: unlocking the mystery of post-shock multiple organ failure. *J Trauma Acute Care Surg.* 2017;82(1):42–50.
341. Williams EC, et al. Precious cargo: modulation of the mesenteric lymph exosome payload after hemorrhagic shock. *J Trauma Acute Care Surg.* 2019;86(1):52–61.
342. Haneklaus M, O’Neill LA, Coll RC. Modulatory mechanisms controlling the NLRP3 inflammasome in inflammation: recent developments. *Curr Opin Immunol.* 2013;25(1):40–5.
343. de Rivero Vaccari JP, et al. Exosome-mediated inflammasome signaling after central nervous system injury. *J Neurochem.* 2016;136(Suppl 1):39–48.
344. Ogura H, et al. Activated platelets enhance microparticle formation and platelet-leukocyte interaction in severe trauma and sepsis. *J Trauma.* 2001;50(5):801–9.
345. Curry N, et al. Levels of procoagulant microvesicles are elevated after traumatic injury and platelet microvesicles are negatively correlated with mortality. *J Extracell Vesicles.* 2014;3:25625.
346. Matijevic N, et al. Cellular microparticle and thrombogram phenotypes in the Prospective Observational Multicenter Major Trauma Transfusion (PROMTTT) study: correlation with coagulopathy. *Thromb Res.* 2014;134(3):652–8.
347. Morel N, et al. Generation of procoagulant microparticles in cerebrospinal fluid and peripheral blood after traumatic brain injury. *J Trauma.* 2008;64(3):698–704.
348. Fujimi S, et al. Increased production of leukocyte microparticles with enhanced expression of adhesion molecules from activated polymorphonuclear leukocytes in severely injured patients. *J Trauma.* 2003;54(1):114–9 (discussion 119–20).
349. Kuravi SJ, et al. Changes in the pattern of plasma extracellular vesicles after severe trauma. *PLoS ONE.* 2017;12(8):e0183640.
350. Mense SM, Zhang L. Heme: a versatile signaling molecule controlling the activities of diverse regulators ranging from transcription factors to MAP kinases. *Cell Res.* 2006;16(8):681–92.
351. Larsen R, et al. A central role for free heme in the pathogenesis of severe sepsis. *Sci Transl Med.* 2010;2(51):51ra71.
352. Li W, et al. Oxidative damage and mitochondrial injuries differ following pneumoperitoneum pressure in rabbit models of varying degrees of hydronephrosis. *Mol Med Rep.* 2018;17(5):6819–27.
353. Rani M, et al. Damage-associated molecular patterns (DAMPs) released after burn are associated with inflammation and monocyte activation. *Burns.* 2017;43(2):297–303.
354. Mendonca R, Silveira AA, Conran N. Red cell DAMPs and inflammation. *Inflamm Res.* 2016;65(9):665–78.
355. Schaer DJ, et al. Haptoglobin, hemopexin, and related defense pathways—basic science, clinical perspectives, and drug development. *Front Physiol.* 2014;5:415.
356. Billich A, et al. Presence of cyclophilin A in synovial fluids of patients with rheumatoid arthritis. *J Exp Med.* 1997;185(5):975–80.
357. Dear JW, et al. Cyclophilin A is a damage-associated molecular pattern molecule that mediates acetaminophen-induced liver injury. *J Immunol.* 2011;187(6):3347–52.
358. Tegeder I, et al. Elevated serum cyclophilin levels in patients with severe sepsis. *J Clin Immunol.* 1997;17(5):380–6.
359. Arun P, et al. Extracellular cyclophilin A protects against blast-induced neuronal injury. *Neurosci Res.* 2013;76(1–2):98–100.
360. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. *Nature.* 2003;425(6957):516–21.
361. Ragab G, Elshahaly M, Bardin T. Gout: an old disease in new perspective—a review. *J Adv Res.* 2017;8(5):495–511.
362. Martinon F, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. *Nature.* 2006;440(7081):237–41.
363. Liang J, et al. Elevated serum uric acid after injury correlates with the early acute kidney in severe burns. *Burns.* 2015;41(8):1724–31.
364. Matzinger P. Tolerance, danger, and the extended family. *Annu Rev Immunol.* 1994;12(1):991–1045.
365. Land W, et al. The beneficial effect of human recombinant superoxide dismutase on acute and chronic rejection events in recipients of cadaveric renal transplants. *Transplantation.* 1994;57(2):211–7.
366. Medzhitov R, Preston-Hurlburt P, Janeway CA. A human homologue of the *Drosophila* Toll protein signals activation of adaptive immunity. *Nature.* 1997;388(6640):394–7.
367. Janeway CA. Approaching the asymptote? Evolution and revolution in immunology. *Cold Spring Harb Symp Quant Biol.* 1989;54(Pt 1):1–13.
368. Land WG. Transfusion-related acute lung injury: the work of DAMPs. *Transfus Med Hemother.* 2013;40(1):3–13.
369. Heil M, Land WG. Danger signals—damaged-self recognition across the tree of life. *Front Plant Sci.* 2014;5:578.
370. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. *Cell.* 2010;140(6):805–20.
371. Bryant CE, et al. Advances in Toll-like receptor biology: modes of activation by diverse stimuli. *Crit Rev Biochem Mol Biol.* 2015;50(5):359–79.
372. Creagh EM, O’Neill LAJ. TLRs, NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity. *Trends Immunol.* 2006;27(8):352–7.
373. Gay NJ, et al. A leucine-rich repeat peptide derived from the *Drosophila* Toll receptor forms extended filaments with a beta-sheet structure. *FEBS Lett.* 1991;291(1):87–91.
374. Wegiel B, Hauser CJ, Otterbein LE. Heme as a danger molecule in pathogen recognition. *Free Radic Biol Med.* 2015;89:651–61.

375. Schwandner R, et al. Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2. *J Biol Chem*. 1999;274(25):17406–9.
376. Poltorak A, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. *Science*. 1998;282(5396):2085–8.
377. Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. *Immunity*. 2011;34(5):637–50.
378. Yu M, et al. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. *Shock*. 2006;26(2):174–9.
379. Franchi L, et al. Function of Nod-like receptors in microbial recognition and host defense. *Immunol Rev*. 2009;227(1):106–28.
380. Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. *Cold Spring Harb Perspect Biol*. 2009;1(6):a001651.
381. Tang D, et al. Hydrogen peroxide stimulates macrophages and monocytes to actively release HMGB1. *J Leukoc Biol*. 2007;81(3):741–7.
382. Hori O, et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphotericin. Mediation of neurite outgrowth and co-expression of rage and amphotericin in the developing nervous system. *J Biol Chem*. 1995;270(43):25752–61.
383. Hofmann MA, et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. *Cell*. 1999;97(7):889–901.
384. Du Yan S, et al. Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease. *Proc Natl Acad Sci U S A*. 1997;94(10):5296–301.
385. Yan SF, Ramasamy R, Schmidt AM. The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease. *Expert Rev Mol Med*. 2009;11:e9.
386. Chen X, et al. RAGE: a potential target for A β -mediated cellular perturbation in Alzheimer's disease. *Curr Mol Med*. 2007;7(8):735–42.
387. Sims GP, et al. HMGB1 and RAGE in inflammation and cancer. *Annu Rev Immunol*. 2010;28:367–88.
388. Sorci G, et al. RAGE in tissue homeostasis, repair and regeneration. *Biochim Biophys Acta*. 2013;1833(1):101–9.
389. Kierdorf K, Fritz G. RAGE regulation and signaling in inflammation and beyond. *J Leukoc Biol*. 2013;94(1):55–68.
390. Ott C, et al. Role of advanced glycation end products in cellular signaling. *Redox Biol*. 2014;2:411–29.
391. Schmidt AM, et al. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. *J Clin Invest*. 2001;108(7):949–55.
392. Bierhaus A, et al. Understanding RAGE, the receptor for advanced glycation end products. *J Mol Med (Berl)*. 2005;83(11):876–86.
393. Wu X, et al. The activation of HMGB1 as a progression factor on inflammation response in normal human bronchial epithelial cells through RAGE/JNK/NF-kappaB pathway. *Mol Cell Biochem*. 2013;380(1–2):249–57.
394. Chen L, et al. Overexpression of RAGE contributes to cigarette smoke-induced nitric oxide generation in COPD. *Lung*. 2014;192(2):267–75.
395. Bauernfeind F, et al. Inflammasomes: current understanding and open questions. *Cell Mol Life Sci*. 2011;68(5):765–83.
396. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. *Mol Cell*. 2002;10(2):417–26.
397. Muruve DA, et al. The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. *Nature*. 2008;452(7183):103–7.
398. Agostini L, et al. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. *Immunity*. 2004;20(3):319–25.
399. Arend WP, Palmer G, Gabay C. IL-1, IL-18, and IL-33 families of cytokines. *Immunol Rev*. 2008;223:20–38.
400. Cerretti DP, et al. Molecular cloning of the interleukin-1 beta converting enzyme. *Science*. 1992;256(5053):97–100.
401. Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes. *Nat Rev Immunol*. 2013;13(6):397–411.
402. Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. *Annu Rev Immunol*. 2009;27:229–65.
403. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. *Annu Rev Immunol*. 2009;27(1):519–50.
404. van de Veerdonk FL, et al. Inflammasome activation and IL-1beta and IL-18 processing during infection. *Trends Immunol*. 2011;32(3):110–6.
405. Rathinam VA, Fitzgerald KA. Inflammasome complexes: emerging mechanisms and effector functions. *Cell*. 2016;165(4):792–800.
406. Schroder K, Tschopp J. The inflammasomes. *Cell*. 2010;140(6):821–32.
407. Vladimer GI, et al. Inflammasomes and host defenses against bacterial infections. *Curr Opin Microbiol*. 2013;16(1):23–31.
408. Walle LV, Lamkanfi M. Pyroptosis. *Curr Biol*. 2016;26(13):R568–72.
409. Hoving JC, Wilson GJ, Brown GD. Signalling C-type lectin receptors, microbial recognition and immunity. *Cell Microbiol*. 2014;16(2):185–94.
410. Dambuza IM, Brown GD. C-type lectins in immunity: recent developments. *Curr Opin Immunol*. 2015;32:21–7.
411. Yamasaki S, et al. Mincle is an ITAM-coupled activating receptor that senses damaged cells. *Nat Immunol*. 2008;9(10):1179–88.
412. Zhou H, et al. IRAKM-Mincle axis links cell death to inflammation: pathophysiological implications for chronic alcoholic liver disease. *Hepatology*. 2016;64(6):1978–93.